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ABSTRACT 
 
Background  
National guidelines suggest 12-18 months of antidepressant treatment for depressed 
patients to maximize the benefits of treatment; however, patterns of medication use 
according to the guidelines are less well understood, especially in older adults who are 
at higher risk of adverse drug events. In addition, selective serotonin reuptake 
inhibitors (SSRIs) are recommended as a first-line therapy for older adults because of 
their favorable adverse event profile; however, several observational studies have 
suggested an association between SSRI use and an increased risk of gastrointestinal 
(GI) bleeding. While this link remains controversial, it is important to evaluate the risk 
of GI bleeding in association with SSRI use, especially in older adults who take 
multiple medications that may increase the risk of GI bleeding. 
 
Objectives 
The purpose of this dissertation is to describe the patterns of antidepressant medication 
use by older adults and quantify the adverse events associated with antidepressant use. 
The third manuscript focuses on methodology to perform a systematic literature 
review of published articles reporting effect measure modification (EMM) and 
characterize the sample size considerations related to EMM.   
 
Methods 
  
In the first manuscript, we performed a cross-sectional study using the Medicare 
Current Beneficiary Survey (MCBS) data from 2004 to 2008. We estimated a 6-month 
discontinuation rate of antidepressant medications in older adults who initiated 
antidepressant treatment following diagnosis with depression. We further developed a 
multivariable logistic regression model to identify predictors of discontinuation of 
antidepressant medication.  
 
For the second manuscript, we conducted a nested case-control study using the MCBS 
data from 2004-2008. We identified cases as all older adults diagnosed with upper GI 
bleeding. Using incidence density sampling, we randomly selected up to 6 controls 
who had no evidence of upper GI bleeding after matching on age (+/- 5 years), gender, 
calendar year, and Charlson comorbidity score. We developed a conditional logistic 
regression model to estimate the risk of upper GI bleeding associated with SSRI use, 
simultaneously adjusting for potential confounders. Furthermore, we evaluated 
whether use of non-steroidal anti-inflammatory drugs (NSAIDs) modified the effect of 
SSRI use on upper GI bleeding.  
 
In the third manuscript, we systematically reviewed the published EMM literature by 
searching the PubMed articles published between January 2008 and June 2013. The 
included studies evaluated EMM by medication use, employed an observational study 
design, and published in English. We characterized these publications and calculated 
frequencies to summarize the percentage of studies identified, including specific 
sample size calculations.  
  
 
Results 
We found that less than 5% of older adults in Medicare programs were diagnosed with 
major depression between 2006 and 2008. Nearly 1 in 2 depressed older adults were 
treated with antidepressant medications and 19.2% initiated medication after 
diagnosis. Of these new users of antidepressant medications, 30.3% discontinued 
medication treatment within 180 days of starting. Living in a metropolitan area was a 
significant predictor of antidepressant discontinuation. In addition, SSRI use did not 
significantly increase the risk of upper GI bleeding in older adults (Adjusted Odds 
Ratio [AOR]=1.3; 95% Confidence Interval [CI], 0.7-2.5). Furthermore, after 
adjusting for confounding factors, use of SSRIs along with NSAIDs was not 
significantly associated with an increased risk of upper GI bleeding (AOR=1.8; 95% 
CI, 0.5-6.7). Through a systematic literature review, we found that none of the studies 
performed sample size calculations specifically related to the EMM, although 14.3% 
of the identified studies mentioned sample size related issues in the study. 
 
Conclusions  
Older adults tend to persist in antidepressant medication use. Information obtained 
from this study can be used by both primary care physicians and policy administrators 
to improve care for older Medicare beneficiaries. Physicians and other healthcare 
providers can utilize the information obtained from this study to more fully evaluate 
the risk-benefit ratio of prescribing specific antidepressants to older adults. In addition, 
the descriptive information obtained in this study (e.g., treatment patterns, average 
  
length of treatment) can provide points of discussion for physicians and other 
healthcare providers when they are working with older adults regarding barriers to 
persistence in antidepressant use and adverse events the beneficiary may be 
experiencing. The third methodologically focused manuscript provided important 
insights into the correct (or incorrect) reporting of sample size related issues in the 
medical literature by elucidating current practices. 
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PREFACE 
 
This dissertation uses the manuscript format. As the prevalence of depression among 
older adults continues to rise, antidepressant treatments have been investigated many 
times over the past decade; however, especially for older adults, many questions 
remain unanswered regarding the benefits and risks of drug therapies according to 
specific clinical and health-system characteristics. The purpose of this dissertation is 
to describe the patterns of antidepressant medication use by community dwelling older 
adults and quantify the adverse events associated with the use of antidepressants. This 
dissertation consists of three manuscripts, as follows: 
 
Manuscript I: Use of Antidepressant Medications in Depressed Older Adults 
and Predictors of Discontinuation of Antidepressant Use 
Manuscript II: Use of Selective Serotonin Reuptake Inhibitors and the Risk of 
Upper Gastrointestinal Bleeding in Older Adults 
Manuscript III: A Systematic Literature Review: Effect Measure Modification 
and Sample Size Considerations in Observational Studies 
 
 ix 
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INTRODUCTION 
 
Epidemiology of Major Depressive Disorder 
Major depressive disorder (MDD) is highly prevalent in the United States. According 
to the National Health and Nutrition Examination Survey (NHANES), approximately 
6.8% of US adults aged 18 years or older had moderate to severe MDD between 2005 
and 2008.[1] The lifetime prevalence of MDD in the US is 18.3%,[2] exceeding the 
lifetime prevalence in Europe (approximately 13%)[3] and Australia (9.7%).[4] 
 
In addition, for older adults MDD is a significant health problem. In 2005, an 
estimated 3.8 million Americans over the age of 65 (approximately 10.4% of that 
population) were diagnosed with depression.[5] In the primary care setting, where 
many elderly depressed patients are identified, 17-37% of elderly patients are 
diagnosed with depression.[6] 
 
In addition to newly developed MDD, relapse and reoccurrence are common. 
Approximately 20% of all patients who recovered from an episode of MDD 
experienced a recurrence within the first 6 months,[7, 8] and more than 1 in 3 patients 
experienced a recurrence within 2-3 years after recovery.[9] A study of community-
dwelling older adults aged 56 years or older in Rotterdam, the Netherlands estimated 
the incidence of depression recurrence at 27.5% (95% confidence interval, 23.7-32.1) 
per 1000 person-years between 1993 and 2005.[10] 
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Economic Burden and Health Service Use for MDD 
A 2004 report from the World Health Organization (WHO) projected MDD as the 
leading cause of burden of disease worldwide by 2030.[11] MDD is a chronic and 
often recurrent disease, leading to impairment of physical and social activities and 
increasing use of health care services.[12] The economic burden of depression is also 
substantial. In 2000, the overall expenditure for MDD, including direct medical costs, 
suicide-related morbidity and mortality costs, and loss of work productivity exceeded 
$83.1 billion in the US.[13] Direct medical costs, including physician’s office visits, 
emergency room visits, hospitalization, antidepressant treatments and psychotherapy 
were estimated at $26.1 billion. Suicide-related morbidity and mortality costs were 
estimated at $5.4 billion, and the costs of unemployment and loss of work 
performance due to MDD were $30.9 billion to $51.5 billion.[13-15] 
 
Depression in Older Adults 
In older adults, depression is often not recognized by physicians and is treated 
inadequately, [16, 17] due to the presence of comorbidities (e.g., arthritis, dementia, 
diabetes, cardiovascular disease), which may mask the symptoms of depression.[18] 
Older adults are generally at higher risk of chronic disease and comorbid depression, 
which may have a substantial influence on their health. MDD is often associated with 
a range of chronic diseases,[19] including cardiovascular disease and 
hypertension;[20] diabetes;[21] cancer;[22] stroke;[23] and arthritis and pain-related 
disorders.[24] Moreover, depression is often linked to a poorer prognosis,[25, 26] 
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because depression may cause poor health behaviors,[27] low adherence to 
treatments,[28-30] or immunodeficiency.[31] 
 
Underdiagnosed and undertreated depression in older adults may contribute to the high 
suicide rate in this population. Older adults account for 15.7% of all suicides in the 
US.[32] Studies revealed that presence of depression was a risk factor for completed 
suicide in older adults.[33, 34] In addition, the Prevention of Suicide in Primary Care 
Elderly: Collaborative Trial (PROSPECT) reported reduced rates of mortality in older 
people with appropriately managed MDD compared to individuals receiving usual 
care,[35] showing the importance of careful recognition and adequate treatment for 
MDD in older adults. 
 
Clinical Guidelines for Treatment of Depression 
As the prevalence of depression is increasing, much research has focused on treatment 
by medication. Based on this evidence, many renowned organizations, including the 
American Psychiatric Association (APA),[36] the National Institute for Health and 
Clinical Excellence (NICE),[37] the British Association for Psychopharmacology 
(BAP),[38] and the Canadian Network for Mood and Anxiety Treatments 
(CANMAT)[39, 40] have developed clinical guidelines for the treatment of 
depression. These guidelines provide similar principles for treating depression, 
including personalized treatment plans, potential long-term treatment, measurement-
based care, and remission treatment.[41] 
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These guidelines note the importance of antidepressant medication treatment in 
managing MDD, regardless of the severity of the disease. The guidelines recommend 
use of antidepressant medications as a first-line therapy for moderate depression. In 
particular, the NICE guidelines emphasize that antidepressant therapy is more cost-
effective than behavioral interventions for acute, moderate MDD.[37] Furthermore, 
the combination of antidepressants with electroconvulsive therapy is recommended for 
patients with severe depression. For patients with mild MDD, the guidelines 
recommend various treatments, including cognitive-behavioral therapy, interpersonal 
therapy, and pharmacotherapy; however, all of the guidelines indicate the need for 
antidepressant treatment for those who have shown partial response or failure of 
psychotherapy.[36-38, 40] 
 
Antidepressant Treatment Duration  
Antidepressant medication therapy can be classified into acute, continuation, and 
maintenance phases based on treatment duration and outcome.[42] The goal of 
treatment in the acute phase is remission of depressive symptoms. The APA guidelines 
require 6-12 weeks of use of the initial selected antidepressants,[36] while the 
BAP/NICE/CANMAT guidelines recommend 8-12 weeks in the acute phase. [37, 38, 
40] The continuation phase follows successful acute phase therapy and aims to 
achieve recovery. The APA guidelines specify 4-9 months of continuous 
treatment[36]; the NICE, BAP and CANMAT recommend at least 6 months of 
continuous use of the antidepressant.[37, 38, 40] The maintenance phase follows the 
continuation phase and aims to prevent reoccurrence. The APA guidelines mention the 
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need for maintenance treatment, especially for patients with chronic and/or recurrent 
(i.e., 3+ histories of) MDD,[36] although the duration of treatment is not specified. 
Most guidelines agree on the need for long-term use of the antidepressant to prevent 
recurrence (e.g., more than 2 years for patients at risk of recurrence).[37, 38, 40]  
 
Antidepressant Medications 
Antidepressant medications commonly prescribed for MDD can be categorized into 
five classes: 1) selective serotonin reuptake inhibitors (SSRIs); 2) serotonin 
norepinephrine reuptake inhibitors (SNRIs); 3) tricyclic antidepressants (TCA); 4) 
monoamine oxidase inhibitors (MAOIs); and 5) other antidepressants, including 
bupropion, mirtazapine, trazodone (also known as second generation 
antidepressants).[43] As the effectiveness of these medications is generally 
comparable between classes, initial selection of antidepressants is based on the 
anticipated risk profiles.[36] For example, due to severe drug-drug interactions, 
MAOIs are restricted to patients who do not respond to other therapy.[44] Similarly, 
TCAs are carefully used in patients who have cardiac risk factors.[45] By contrast, 
serotonin reuptake inhibitors (e.g., SSRIs) are considered a lower risk choice than 
other classes of medications due to their favorable adverse event profiles.[46, 47] 
 
Effect Measure Modification 
Effect measure modification (EMM) is a phenomenon in which an association 
between an exposure and outcome varies by a third factor.[48] The key to detecting 
modified effects between groups is to have an adequate sample size for each group to 
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ensure sufficient power to detect and characterize EMM. Researchers should conduct 
and report sample size considerations related to EMM in the medical literature. 
Nevertheless, no standardized guide to reporting sample size related issues has been 
provided, especially research related to EMM utilizing large quantities of 
administrative data. 
 
Objectives 
The purpose of this dissertation is to describe the patterns of antidepressant use by 
community-dwelling older adults and quantify the adverse events associated with use 
of antidepressant medications. According to the guidelines, initial selection of 
antidepressants is generally based on the risk profiles of these medications because the 
efficacy of the medications is relatively comparable.[36-38, 40] Furthermore, in order 
to achieve maximum benefits of antidepressant treatment, the guidelines suggest 12-18 
months of medication use; however, patterns of antidepressant use according to the 
guidelines are less well understood, especially in older adults, who are at higher risk of 
adverse drug events.[49] In addition, SSRIs are recommended as the first-line 
treatment for depressed older adults because of their favorable adverse event 
profile[36]; however, a safety concern has recently been raised. Several studies 
reported a potential association between gastrointestinal (GI) bleeding and the use of 
antidepressants,[50-53] while other studies do not support such a relationship.[54-56] 
These conflicting findings may warrant further studies, and this association has not yet 
been examined with in older adults in the US.  
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This dissertation has three specific aims related to antidepressant use in older adults, 
namely: 
1. To describe patterns of persistence with antidepressant medication use and 
identify factors associated with non-persistence in older adults. 
2. To examine the association between the use of SSRIs and the risk of GI 
bleeding in older adults.   
3. To perform a systematic review of published articles reporting EMM and 
characterize the sample size considerations related to EMM reported in these 
studies.   
 
The corresponding hypotheses for each of the aforementioned studies are: 
1. The duration of treatment with antidepressants will be suboptimal according to 
national guidelines, and subgroups of the population may be more likely to 
demonstrate low persistence in antidepressant therapy. 
2. The use of SSRIs increases the risk of GI bleeding in older adults. Further, this 
risk will be modified by concomitant medications. 
3. Few published pharmacoepidemiologic studies assessing EMM utilize and 
present formal sample size calculations in the published manuscript. 
 8 
 
REFERENCE 
1. Reeves WC, Strine TW, Pratt LA, Thompson W, Ahluwalia I, Dhingra SS, et al. 
Mental Illness Surveillance Among Adults in the United States: U.S. Dept. of 
Health and Human Services, Public Health Service, Centers for Disease Control; 
2011. Report No. 0892-3787. 
2. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-
month and lifetime prevalence and lifetime morbid risk of anxiety and mood 
disorders in the United States. International Journal of Methods in Psychiatric 
Research. 2012;21(3):169-84. 
3. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. 
Psychotropic drug utilization in Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica 
Scandinavica. 2004;109:55-64. 
4. Australian Bureau of Statistics. Australian Health Survey: First Results, 2011-12.  
2012  [cited June 02, 2013]; Available from: 
http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/1680ECA402368CCFC
A257AC90015AA4E/$File/4364.0.55.001.pdf 
5. Heo M, Murphy CF, Fontaine KR, Bruce ML, Alexopoulos GS. Population 
projection of US adults with lifetime experience of depressive disorder by age 
and sex from year 2005 to 2050. International Journal of Geriatric Psychiatry. 
2008;23(12):1266-70. 
6. Alexopoulos GS, Katz IR, Reynolds CFI, Carpenter D, Docherty JP, Ross RW. 
Pharmacotherapy of depression in older patients: a summary of the expert 
consensus guidelines. Journal of Psychiatric Practice®. 2001;7(6):361-76. 
7. Keller MB, Lavori PW, Lewis CE, Klerman GL. Predictors of relapse in major 
depressive disorder. JAMA: The Journal of the American Medical Association. 
1983;250(24):3299-304. 
8. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. 
Multiple recurrences of major depressive disorder. The American Journal of 
Psychiatry. 2000;157(2):229-33. 
9. Eaton WW, Shao H, Nestadt G, Lee BH, Bienvenu OJ, Zandi P. Population-based 
study of first onset and chronicity in major depressive disorder. Archives of 
General Psychiatry. 2008;65(5):513-20. 
10. Luijendijk HJ, van den Berg JF, Dekker MJ, van Tuijl HR, Otte W, Smit F, et al. 
Incidence and recurrence of late-life depression. Archives of General Psychiatry. 
2008;65(12):1394-401. 
 9 
 
11. World Health Organization (WHO). The Global Burden of Disease: 2004 
Updates.  2008  [cited June 02, 2013]; Available from: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_f
ull.pdf 
12. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The 
epidemiology of major depressive disorder: results from the National 
Comorbidity Survey Replication (NCS-R). JAMA: The Journal of The American 
Medical Association. 2003;289(23):3095-105. 
13. Greenberg PE, Kessler R, Birnbaum H, Leong S, Lowe S, Berglund P, et al. The 
economic burden of depression in the United States: how did it change between 
1990 and 2000? The Journal of Clinical Psychiatry. 2003;64(12):1465-75. 
14. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive 
work time among US workers with depression. JAMA: The Journal of the 
American Medical Association. 2003;289(23):3135-44. 
15. Greenberg PE, Birnbaum HG. The economic burden of depression in the US: 
societal and patient perspectives. Expert Opinion on Pharmacotherapy. 
2005;6(3):369-76. 
16. Hirschfeld RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. 
The national depressive and manic-depressive association consensus statement on 
the undertreatment of depression. JAMA: The Journal of the American Medical 
Association. 1997 January 22, 1997;277(4):333-40. 
17. Lebowitz BD, Pearson JL, Schneider LS, Reynolds CF, Alexopoulos GS, Bruce 
ML, et al. Diagnosis and treatment of depression in late life. JAMA: The Journal 
of the American Medical Association. 1997 October 8, 1997;278(14):1186-90. 
18. Volz HP, Möller HJ. Antidepressant drug therapy in the elderly - a critical review 
of the controlled clinical trials conducted since 1980. Pharmacopsychiatry. 1994 
13.03.2008;27(03):93,100. 
19. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and 
depressive disorders. Preventing Chronic Disease. 2005;2(1):A14. 
20. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. 
Depression and the risk for cardiovascular diseases: systematic review and meta 
analysis. International Journal of Geriatric Psychiatry. 2007;22(7):613-26. 
21. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The Prevalence of 
Comorbid Depression in Adults With Diabetes: a meta-analysis. Diabetes Care. 
2001 June 1, 2001;24(6):1069-78. 
 10 
 
22. Penninx BWJH, Guralnik JM, Havlik RJ, Pahor M, Ferrucci L, Cerhan JR, et al. 
Chronically depressed mood and cancer risk in older persons. Journal of the 
National Cancer Institute. 1998 December 16, 1998;90(24):1888-93. 
23. Ohira T, Iso H, Satoh S, Sankai T, Tanigawa T, Ogawa Y, et al. Prospective study 
of depressive symptoms and risk of stroke among Japanese. Stroke. 2001 April 1, 
2001;32(4):903-8. 
24. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with 
chronic pain: an examination in a nationally representative sample. Pain. 
2003;106(1–2):127-33. 
25. Gillen R, Tennen H, McKee TE, Gernert-Dott P, Affleck G. Depressive 
symptoms and history of depression predict rehabilitation efficiency in stroke 
patients. Archives of Physical Medicine and Rehabilitation. 2001;82(12):1645-9. 
26. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology 
among diabetic adults. Diabetes Care. 1997 April 1, 1997;20(4):585-90. 
27. Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid 
substance use disorders. Current Opinion in Psychiatry. 2008;21(1):14-8. 
28. Cluley S, Cochrane GM. Psychological disorder in asthma is associated with poor 
control and poor adherence to inhaled steroids. Respiratory Medicine. 
2001;95(1):37-9. 
29. Krauskopf KA, Sofianou A, Goel MS, Wolf MS, Wilson EA, Martynenko ME, et 
al. Depressive symptoms, low adherence, and poor asthma outcomes in the 
elderly. The Journal of asthma : official journal of the Association for the Care of 
Asthma. 2013 Apr;50(3):260-6. 
30. DiMatteo M, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of anxiety 
and depression on patient adherence. Archives of Internal Medicine. 
2000;160(14):2101-7. 
31. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways 
to morbidity and mortality. Journal of Psychosomatic Research. 2002;53(4):873-
6. 
32. Centers for Disease Control and Prevention. Web-based Injury Statistics Query 
and Reporting System (WISQARS).  2010  [cited July 27, 2013]; Available from: 
http://www.cdc.gov/injury/wisqars/index.html 
33. Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED. 
Relationships of age and axis I diagnoses in victims of completed suicide: a 
psychological autopsy study. The American Journal of Psychiatry. 1996 
Aug;153(8):1001-8. 
 11 
 
34. Henriksson MM, Marttunen MJ, Isometsa ET, Heikkinen ME, Aro HM, 
Kuoppasalmi KI, et al. Mental disorders in elderly suicide. International 
Psychogeriatrics. 1995 Summer;7(2):275-86. 
35. Gallo JJ, Morales KH, Bogner HR, Raue PJ, Zee J, Bruce ML, et al. Long term 
effect of depression care management on mortality in older adults: follow-up of 
cluster randomized clinical trial in primary care. BMJ: British Medical Journal. 
2013 2013-06-05 14:33:02;346. 
36. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi 
MH, et al. Practice Guideline for the Treatment of Patients with Major 
Depressive Disorder. Third Edition; 2010. 
37. National Institute for Health and Clinical Excellence. Depression : The Treatment 
and Management of Depression in Adults (Updated Edition): British 
Psychological Society; 2010. 
38. Anderson I, Ferrier I, Baldwin R, Cowen P, Howard L, Lewis G, et al. Evidence-
based guidelines for treating depressive disorders with antidepressants: a revision 
of the 2000 British Association for Psychopharmacology guidelines. Journal of 
Psychopharmacology. 2008 June 1, 2008;22(4):343-96. 
39. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network 
for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the 
management of major depressive disorder in adults. Journal of Affective 
Disorders. 2009;117, Supplement 1(0):S1-S2. 
40. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et 
al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical 
guidelines for the management of major depressive disorder in adults.: III. 
Pharmacotherapy. Journal of Affective Disorders. 2009;117, Supplement 
1(0):S26-S43. 
41. Davidson JRT. Major depressive disorder treatment guidelines in America and 
Europe. The Journal of Clinical Psychiatry. 2010;71 Suppl E1(suppl e1):e04. 
42. Kupfer DJ. Long-term treatment of depression. The Journal of Clinical 
Psychiatry. 1991;52 Suppl:28-34. 
43. Shargel L, Mutnick AH, Souney PF, Swanson LN, editors. Comprehensive 
Pharmacy Review. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2008. 
44. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. 
Cleveland Clinic Journal of Medicine. 2010 December 1, 2010;77(12):859-61, 
65, 72-73, 77-78, 82. 
 12 
 
45. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and 
the risk of sudden cardiac death. Clinical Pharmacology & Therapeutics. 
2004;75(3):234-41. 
46. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic 
antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective 
Disorders. 2000 4//;58(1):19-36. 
47. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF. Fluoxetine versus 
phenelzine in atypical depression. Biological Psychiatry. 1996 
11/15/;40(10):1017-20. 
48. Last JM. A Dictionary of Epidemiology. Fourth Edition: Oxford University Press, 
Inc.; 2001. 
49. Miller GC, Britt HC, Valenti L. Adverse drug events in general practice patients 
in Australia. Medical Journal of Australia. 2006;184(7):321-4. 
50. Dalton SO, Johansen C, Mellemkjær L, Sørensen HT, Nørgård B, Olsen JH. Use 
of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract 
bleeding: a population-based cohort study. Archives of internal medicine. 
2003;163(1):59-64. 
51. de Abajo FJ, Rodríguez LAG, Montero D. Association between selective 
serotonin reuptake inhibitors and upper gastrointestinal bleeding: population 
based case-control study. BMJ: British Medical Journal. 1999;319(7217):1106-9. 
52. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin 
reuptake inhibitors are associated with a modest increase in the risk of upper 
gastrointestinal bleeding. The American Journal of Gastroenterology. 
2009;104(6):1475-82. 
53. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin 
reuptake by antidepressants and upper gastrointestinal bleeding in elderly 
patients: retrospective cohort study. BMJ: British medical journal (Clinical 
research ed). 2001 September 22, 2001;323(7314):655-8. 
54. Carvajal A, Ortega S, Del Olmo L, Vidal X, Aguirre C, Ruiz B, et al. Selective 
serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study. 
PLoS ONE. 2011;6(5):e19819. 
55. Vidal X, Ibáñez L, Vendrell L, Conforti A, Laporte JR. Risk of upper 
gastrointestinal bleeding and the degree of serotonin reuptake inhibition by 
antidepressants: a case-control study. Drug Safety. 2008;31(2):159-68. 
56. Williams D, Kelly A, Feely J, Dunn NR, Pearce GL, Shakir SAW, et al. 
Association between SSRIs and upper gastrointestinal bleeding. BMJ: British 
Medical Journal. 2000;320(7246):1405-6. 
 13 
 
Manuscript I. Use of Antidepressant Medications in Depressed Older Adults and 
Predictors of Discontinuation of Antidepressant Use 
 
BACKGROUND 
Clinical trials suggest that discontinuation of antidepressant medications is associated 
with a high risk of relapse and reoccurrence in patients diagnosed with depression,[1-
3] indicating that continuous use of antidepressants is key to achieving remission of 
depressive symptoms and  preventing recurrence of the disease. To maximize the 
benefits of medication therapy, guidelines recommend that the initial treatment last 
12-18 months.[4, 5]  
 
Despite the well-known benefit of continuous use of antidepressants, the rate of 
persistence in antidepressant use in the real world remains suboptimal. A study based 
on data from the Medical Expenditure Panel Survey (MEPS) reported that 42.4% of 
US adults diagnosed with depression discontinued their antidepressant medication 
therapy within the first 30 days; 72.4% stopped taking antidepressants during the next 
90 days.[6] In addition, 6-month discontinuation rates ranged from 53.0 to 87.6%.[7-
9] Similarly, European studies showed low persistence rates for antidepressant use: 
more than 50% of antidepressant users discontinued their medication within 6 
months.[10, 11] 
 
Factors Associated with Medication Discontinuation 
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There is a wide range of reasons for medication treatment discontinuation, including 
the patient’s individual characteristics (e.g., socioeconomic status, side effects), the 
patient-physician relationship, and the accessibility and quality of health care.[12, 13] 
 
A systematic literature review by Rivero-Santana el al. summarized predictors of non-
adherence to antidepressant therapy in depressed patients.[14] The authors evaluated 
various socioeconomic and clinical characteristics and noted that the most consistent 
predictors were age, race/ethnicity, cognitive impairment and substance use. 
Furthermore, Linden et al. reported that drug-induced adverse events limited 
continuous use of antidepressant medications.[15]  
 
Several qualitative studies addressed barriers to continuation of medication treatments, 
including: 1) limited confidence in the physicians; 2) limited involvement in making 
decisions regarding antidepressant treatments; 3) poor knowledge of antidepressant 
use; 4) self-reported changes in depression; 5) pessimism about the curability of 
depression; and 6) negative expectations regarding aging.[16-18] In addition, health 
care systems affecting access to and quality of care are associated with medication 
adherence.[13]  
 
Unique Clinical Challenges in Older Adults 
Compared to younger adults, older adults are more likely to have several comorbid 
diseases and to take multiple medications simultaneously. Moreover, older people may 
show slower improvement in symptoms than younger adults in response to 
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medication.[19] Guidelines recommend appropriate antidepressant dose adjustments 
in the geriatric population because older adults may present an altered profile of drug 
absorption and metabolism, which could modify the efficacy of treatments or 
contribute to the development of unintended adverse events.[5, 20]  
 
In this study, we described patterns of antidepressant use in older adults. We 
hypothesized that antidepressant medication treatment would be suboptimal 
(according to national guidelines) and further, subgroups of the population would be 
more prone to suboptimal persistence in antidepressant use. To evaluate these 
hypotheses, we calculated how long older adults persisted in antidepressant use and 
compared our findings to the recommendations for treatment by the national 
guidelines (e.g., how many respondents take antidepressants through the 
recommended acute, continuous, and maintenance phases of treatment). We further 
identified independent predictors of discontinuation of antidepressant treatment in 
older adults. 
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METHOD 
To achieve our aims, we employed a retrospective, cross-sectional study design to 
characterize the use of antidepressant medications in older adults with depression as 
well as quantify the rates of persistence to their antidepressant treatments. 
 
Data Source 
We used the Medicare Current Beneficiary Survey (MCBS) from 2004 to 2008. The 
MCBS is a nationally representative survey of a sample of older adults and persons 
with disabilities.[21] The MCBS survey questionnaire was originally designed by the 
Center for Medicare and Medicaid Services (CMS) to facilitate administration, 
monitoring and assessment of the Medicare programs.[22] The MCBS consists of two 
sections, including the Cost and Use file (use of health care services, costs, and event 
level information) and the Access to Care file (information regarding accessibility, 
usual source of care, and satisfaction with the services). We utilized the Cost and Use 
files for this dissertation. The survey instruments used to collect data in the MCBS are 
publicly available on the CMS website 
(https://www.cms.gov/MCBS/Ques/list.asp#TopOfPage). 
 
The MCBS includes approximately 12,000 beneficiaries annually who completed the 
survey. The survey is a 4-year rotating panel, with each panel interviewing ≈4,000 
persons. Each year, the oldest panel retires in May through August, with the new panel 
starting in September through December. Each panel is interviewed three times 
(rounds) per year, for 12 consecutive rounds. Survey responses are collected through 
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computer assisted in-person interview (CAPI). Community interviews are performed 
face-to-face with respondents, while facility interviews are administered to nurses 
and/or other primary caregivers who can answer questions regarding physical 
functioning and medical treatment for the sample. The MCBS generally has a high 
response rate of 84.3-97.3%, high data completeness, and limited loss to follow-up 
(approximately 8-10%).[23-25]  
 
The MCBS Cost and Use file provides comprehensive information, including 
beneficiaries’ demographic and socioeconomic characteristics, health status and 
behaviors (e.g., smoking status, alcohol consumption), health insurance coverage, 
medical histories, prescription drug use, and deaths. In addition, the MCBS is linked 
to the Medicare Part A and B claim files, which supplement the survey data with 
diagnoses, utilization and payment information. 
 
Since the implementation of the Medicare Part D prescription drug program in January 
2006, the MCBS has been linked to Medicare Part D claims data.[26] Before 2006, 
‘Prescription Medicine Event’ files were collected every four months by interview. 
While the MCBS interviewer was visiting the survey respondents, the interviewer 
inspected the bottle of medicines that the respondents were taking and verified the date 
when the corresponding medications were prescribed. However, date of prescription 
and day’s supply were not provided in the prescription medicine event files. After 
2006, approximately 60% of the Medicare beneficiaries were enrolled in Part D 
programs,[27] and comprehensive prescription information, including date of 
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prescription, day’s supply, and quantity have been available for the Part D enrollees in 
the MCBS data. Therefore, it became possible to reliably measure utilization patterns 
of medications for individual beneficiaries using the MCBS data. 
 
All data being used for this research is de-identified and previously collected for 
research or administrative purposes. This study was reviewed by the Institutional 
Review Board at the University of Rhode Island and granted exempt status. 
 
Study Population Identification 
Because we were interested in the patterns of antidepressant use by depressed older 
adults, we restricted a sample of this study to community-dwelling older adults with 
diagnosed depression. We assembled a subsample of all 2006-2008 MCBS 
respondents due to the limited availability of the prescription drug event claims data 
collected for Medicare Part D. 
 
We first identified beneficiaries who were at least 65 years of age using Medicare 
Administrative Identification files. We then identified community-dwelling 
beneficiaries. Based on resident records, we included persons who lived in the 
community for the entire year and those who lived in the community most of the time 
but spend part of the year in a facility. Next, we utilized outpatient and inpatient 
claims data to identify patients diagnosed with depression. Diagnosis codes for major 
depression include the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes 296.2, 296.3, 300.4, 309.1 309.2, 298.0, and 
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311.[28, 29] During the study period, we observed the first date of diagnosis with 
depression and defined it as the index date. We followed patients for 1 year from the 
index date to characterize the patterns of antidepressant medication use. 
 
Within the eligible sample, we evaluated prescription drug event files to identify older 
adults who were newly treated with antidepressant medications. We first excluded 
patients who were not prescribed any antidepressant medications during the follow-up 
period. We then excluded patients who were exposed to antidepressants within the 90 
days prior to the index date. We set this exclusion criterion in order to identify new 
users of antidepressant medications. Further, we excluded individuals who were lost to 
follow-up within 180 days from the index date to ensure a minimal period in which to 
characterize persistence patterns. 
 
Identification of Antidepressant Medication Use 
Using therapeutic class codes in prescription drug event files, we first identified the 
generic/brand names of possible antidepressant medications under the subclass of ‘80’ 
(Psychotherapeutic drugs) or ‘97’ (Psychotherapeutic drugs). Next, we reviewed text 
strings of the generic/brand names of antidepressants and then manually reviewed 
identified drugs for accidental inclusions and omissions.  
 
We categorized antidepressant medications into five groups, including: 1) SSRIs (i.e., 
citalopram, escitalopram, fluoxetine, paroxetine, sertraline); 2) SNRIs (i.e., 
desvenlafaxine, duloxetine, venlafaxine); 3) TCAs (i.e., amitriptyline, amoxapine, 
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clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, 
protrptyline); 4) MAOIs (i.e., phenelzine); and 5) other antidepressants (i.e., 
bupropion, mirtazapine, trazodone, nefazodone).[30] Patients treated with combination 
antidepressant therapy (N=18, 18.2%) or those who switched therapy (N=7, 7.1%) 
were classified based on the antidepressant medication taken for the longest period. 
 
Definition and Measurement of Persistence 
We defined persistence as the number of days from the start of medication therapy to 
discontinuation of that therapy.[31] To define discontinuation of the treatment, we 
identified gaps in treatment longer than 60 days.  
 
To quantify rates of non-persistence in antidepressant use, we used the Health 
Effectiveness Data and Information Set (HEDIS®) measurement. HEDIS is a set of 
standardized measurement in health care performance. It defines measures addressing 
the incomplete prescribing and use of antidepressants among adult patients who are 
newly diagnosed with depression.[32] According to HEDIS, effective acute phase 
treatment is defined as the percentage of patients continuing their antidepressant 
medication treatment for at least 84 days (12 weeks).[33] Similarly, effective 
continuation phase treatment is defined as the percentage of patients who use 
antidepressant medications for at least 180 days (6 months). We further examined the 
84-day and 180-day discontinuation rates by each pharmacological class of 
antidepressants. 
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Independent Predictors 
We examined demographic and clinical characteristics that potentially predict 
antidepressant discontinuation. Demographic characteristics included age (65-74 years 
old, 75-84 years old, 85 years or older), gender, race/ethnicity (non-Hispanic White 
[NHW], non-Hispanic Black [NHB], Hispanic, Other), US region of residence 
(Northeast, South, Midwest, West), residence type (metropolitan area vs. non-
metropolitan area), marital status (married, widow, divorced/separated/never married), 
education (college degree or more, high school graduate, no high school diploma), the 
number of children living (0, 1-2, ≥3), and income (less than $25,000 vs. more than 
$25,000). Further, we utilized self-reported general health status. We dichotomized the 
responses on the overall health status compared to other people of the same age as 
excellent/very good/good versus fair/poor. Responses for health status compared to 
one year ago were categorized as 1) much better/somewhat better, 2) about the same, 
and 3) somewhat worse/much worse. 
 
Amongst clinical characteristics, we assessed comorbid conditions and use of 
concurrent medications. We used inpatient/outpatient claims data to identify 
comorbidities of interest. During a visit to a physician’s office, up to nine ICD-9-CM 
diagnosis codes are captured. Using the Elixhauser comorbidity index algorithm,[34] 
we first identified 31 individual comorbid diseases. Similar to the Charlson 
comorbidity index score, the Elixhauser comorbidity index score condensed into one 
number can reliably summarize the burden of disease and adequately discriminate 
hospital mortality.[35] Therefore, we created a composite variable summing each 
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Elixhauser comorbidity score except depression and considered this composite 
variable as a continuous variable ranging from 0 to 30. We further identified certain 
conditions related to MDD, including pain-related disorders (e.g., headaches, lower 
back pain, fibromyalgia, neuropathic pain, and other pain), sleep disorders, and other 
mental disorders other than depression (e.g., bipolar disorder, anxiety disorders, 
obsessive compulsive disorder, fatigue, and eating disorders). 
 
For overall medication use, we calculated the total number of medications taken by the 
beneficiaries during the study period, excluding antidepressant medications. We 
restricted this count to oral, buccal, sublingual, and inhalation agents and excluded 
non-oral administration route agents (e.g., injections, topical agents). We then 
calculated the number of medications prescribed per month and then divided the 
number of monthly medications by the eligible follow-up period of the individual. 
Moreover, we identified each class of medications using the same approach to identify 
antidepressants. Concurrent medication groups identified in this study included 
antihypertensive agents, oral antidiabetic agents, cholesterol-lowering medications, 
pain management medications (e.g., NSAIDs), hypnotics/sedatives, and 
anticonvulsants. 
 
Statistical Analyses 
We generated descriptive statistics including proportions, means, and medians to 
describe the overall prevalence of depression in older adults and common 
comorbidities associated with depression in this population. In addition, we described 
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the prevalence and incidence of overall and specific use of antidepressant medications 
in older adults diagnosed with MDD. We further characterized the overall sample 
characteristics, including age, gender, race/ethnicity, health status (as measured by the 
Elixhauser comorbidity index), and concurrent medication use. 
 
Bivariate Analyses 
We conducted bivariate analyses to assess differences in characteristics between the 6-
month non-persistent group and the persistent group. We evaluated demographic 
characteristics, clinical comorbidities, and concurrent medications between the two 
groups. We used chi-squared analyses to compare differences in categorical variables 
and t-tests for continuous variables. 
 
Multivariable Logistic Regression Model 
We developed a multivariable logistic regression model to identify independent 
predictors of non-persistence in the antidepressant use suggested by national 
guidelines. The dependent variable was non-persistence in antidepressant use within 6 
months (coded as 1=discontinuation of the treatment within 180 days; 0=otherwise). 
We considered demographic characteristics, clinical diagnoses, and concurrent use of 
medications as potential predictors. We developed a preliminary model by first 
including all variables identified as potential predictors during the bivariate analyses. 
Any factors with a p-value less than 0.25 between the non-persistence group and the 
persistence group were included in the preliminary model. We then refined this model 
by sequentially removing variables from the model if the variables did not predict 
 24 
 
discontinuation of therapy (P>0.10). We confirmed variable removal through 
likelihood ratio testing. After a final model resulted, we checked for multicollinearity 
(using Variance Inflation Factor [VIF]) and two-way interactions (through likelihood 
ratio testing) between all covariates in the final model. We also performed the Hosmer 
and Lemeshow Goodness-of-Fit test for the final model. All statistical tests were 
conducted with a two-tailed alpha, and all analyses were performed using SAS 
software (SAS Institute Inc., Cary, NC, version 9.3). 
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RESULTS 
Overall, the prevalence of major depression in older Medicare beneficiaries living in 
the community was 4.5% (=739/16601). Of these depressed individuals, 50.3% took 
antidepressant medications and 19.2% were newly treated with an antidepressant 
medication following the diagnosis of depression. 
 
Sample Characteristics 
We identified 99 community-dwelling older Medicare beneficiaries who were 
diagnosed with depression and who initiated antidepressant treatment within one year 
of the index date. As presented in Table 1.2, mean of age in this eligible sample was 
77.4 years. Most of the patients were female (n=73, 73.7%) and non-Hispanic White 
(n=85, 85.9). The average number of comorbid conditions except depression (mean ± 
Standard Deviation [SD]) was 4.9 ± 3.1, and the median number of comorbidities was 
4.0. In addition, the average number of medications taken by these patients other than 
antidepressants was 6.0 ± 2.7, and the median number of medications was 5.4. 
Community-dwelling older beneficiaries diagnosed with depression had high rates of 
comorbidity, including hypertension (83.8%), pain-related disease (73.7%), 
dyslipidemia (61.6%), cardiovascular disease (56.6%), mental disorders other than 
major depression (54.6%), arthritis (52.5%), fluid and electrolyte disorders (48.5%), 
chronic obstructive pulmonary disease (COPD, 39.4%), and diabetes mellitus (32.3%).  
 
Antidepressant Treatment Discontinuation Rates 
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Within the eligible sample, the mean number of days of antidepressant treatment one 
year from the index date was 293 ± 93 days, and the median was 339 days (range 7-
365 days). We observed a gap between the date of diagnosis of depression and the 
date of initiation of antidepressant therapy. The mean lag time was 72 ± 93 days, and 
the median was 26 days (range 0-358 days). 
 
Approximately 8.1% of the patients who initiated antidepressant medication therapy 
for diagnosed depression discontinued their treatment during the first 30 days 
following initiation. The discontinuation rate within 84 days (12 weeks) from the 
antidepressant treatment initiation was 13.1%. Nearly 1 in 3 patients (30.3%) 
discontinued their antidepressants by 6 months (180 days), and the discontinuation 
rate increased to 75.8% at 1 year (Table 1.1).  
 
Within subgroup analyses, the pattern of medication discontinuation by antidepressant 
classes (SSRI/SNRI vs. TCA/Other) was similar to that of overall use. Patients using 
SSRIs or SNRIs showed higher rates of discontinuation than TCA or Other 
antidepressant users. In the acute phase, 13.6% of SSRI/SNRI users discontinued the 
medications, whereas 12.1% of TCA/Other users discontinued their medications. 
Similarly, the 6-month discontinuation rate was 34.9% in the SSRI/SNRI group and 
21.2% in the TCA/Other group. The difference in discontinuation rates reached 27.3% 
at the 1-year follow-up (84.9% for SSRI/SNRI users vs. 57.6% for TCA/Other users; 
p=0.003). 
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Bivariate Analyses by Persistence Status 
In Table 1.2, we present the demographic characteristics of the 99 patients stratified by 
persistence. Of the 99, 69.7% continued antidepressant therapy for 180 days, whereas 
30.3% discontinued treatment within 180 days. First, we found that patients in the 
non-persistence group tended to be older than those in the persistence group. 
Approximately 39.1% of people in the persistence group were between 75-84 years of 
age, while 23.3% of non-persistent patients were in the same age group. On the 
contrary, 17.4% of the persistent group were 85 years of age or older, whereas 33.3% 
of the non-persistent group were over 85 years of age. The percentage of female 
beneficiaries was higher in the non-persistent group (80.0%) compared to the 
persistent group (71.0%). The proportion of non-Hispanic White patients in the non-
persistent group (83.3%) was slightly less than the proportion in the persistent group 
(87.0%). Older Medicare beneficiaries who discontinued their antidepressant 
treatment were more likely living in metropolitan areas (70.0%) compared to those 
who persisted in therapy (52.2%). There was approximately a 20% difference in the 
proportion of widows in the non-persistent group versus the persistence group: 66.7% 
of patients in the non-persistent group were widowed, while 46.4% of patients in the 
persistent group were widowed. Lastly, persons whose annual income was less than 
$25,000 were slightly better represented in the non-persistence group (86.7%) 
compared to the persistence group (82.6%). No differences in demographic 
characteristics between the non-persistent group and the persistent group were 
statistically significant at alpha equals 0.05. 
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Clinical characteristics of community-dwelling depressed older Medicare beneficiaries 
stratified by the status of antidepressant treatment persistence are presented in Table 
1.3. Analyzing self-reported overall health suggested better overall health in the non-
persistent group. For people with good health status: 53.3% in the non-persistent 
group vs. 39.1% in the persistent group; for individual with fair/poor health status: 
46.7% in the non-persistent group vs. 60.9% in the persistent group. In addition, older 
depressed Medicare beneficiaries in the non-persistence group had fewer comorbid 
conditions (mean ± SD, 4.4 ± 3.1) than those in the persistent group (5.1 ± 3.0). 
Compared to people in the persistent group, those who discontinued their 
antidepressant treatments within 180 days were less likely to have chronic diseases, 
including hypertension (80.0% for those in the non-persistent group vs. 85.5% for 
those in the persistent group), cardiovascular disease (46.7% vs. 60.9%), COPD 
(33.3% vs. 42.0%), diabetes (23.3% vs. 36.2%), and cancer (3.3% vs. 13.0%). On the 
contrary, the non-persistent group had a higher prevalence of fluid and electrolyte 
disorders than the persistent group (56.7% vs. 44.9%). The prevalence of arthritis and 
pain-related disorders was similar between the groups.  
 
The average number of medications (excluding antidepressants) taken by older adults 
was 4.7 ± 2.4 in the non-persistent group and 5.6 ± 2.7 in the persistent group. As for 
comorbidities, the non-persistent group showed lower rates of use of antihypertensive 
medications (86.7% in the non-persistent group vs. 97.1% in the persistent group, 
p=0.05), antidiabetic medications (13.3% vs. 24.6%), anticoagulants (16.7% vs. 
37.7%, p=0.04), and acid suppressive medications (46.7% vs. 63.8%). The proportion 
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of SSRI or SNRI users in the non-persistent group was slightly higher than in the 
persistent group, while the proportion of TCA or other antidepressant users was 
slightly lower in the non-persistent group. 
 
Independent Predictors for Non-persistence 
In Table 1.4, we described independent predictors of antidepressant discontinuation 
within 180 days as adjusted odds ratios and corresponding 95% confidence intervals 
from multivariable analyses. The significant predictors of discontinuation included 
residence type (metropolitan area vs. non-metropolitan area). Older adults living in 
metropolitan areas were 3.5 times more likely to discontinue their antidepressant 
treatments compared to those who lived in non-metropolitan areas (Adjusted Odds 
Ratio [AOR]=3.5; 95% Confidence Interval [CI], 1.2-10.2). No other potential 
predictors significantly predicted non-persistence of antidepressant medication use. 
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DISCUSSION 
We described patterns of antidepressant use in community-dwelling older adults who 
were Medicare beneficiaries. We found that less than 5% of older adults were 
diagnosed with major depression. Approximately 1 in 2 depressed patients were 
treated with antidepressant medications and 19.2% of depressed older adults initiated 
antidepressant treatment following the diagnosis for depression. Of these new users of 
antidepressant medications, one-third discontinued their medication within 180 days. 
We found that older adults living in metropolitan areas were significantly more likely 
to discontinue treatment. Our findings suggest that new users of antidepressants in 
depressed older adults tend to persist in treatment; however, physicians should pay 
careful attention when prescribing antidepressants to older adults living in 
metropolitan areas to encourage persistence in treatment.  
 
Discontinuation Rates 
Rates of discontinuation of antidepressant medication treatments at 6 months varied 
from 12.2% to 87.6% in published studies,[7-9, 36-40] with our estimate of 30.3% 
falling towards the lower end of this range. One possible explanation for the diverse 
rates of discontinuation in the published literature might be the various definitions for 
discontinuation used in each of the studies. Discontinuation in the analysis of 
administrative claims data was defined as no evidence of a fill/refill[37] or gaps 
between prescriptions of 15 days,[8] 30 days,[39] 45 days,[40] or 1.5 times the 
supply.[38]  
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The relatively lower rate of discontinuation in our study may be explained by 
methodological differences in the definition of persistence and the impact of new 
health care service implementation. We identified non-persistence by 60-day gaps 
between prescriptions. This gap is larger than that used in published articles,[8, 39, 40] 
and therefore may indicate a higher rate of persistence. In addition, our focus was on 
the continuity of any antidepressant medication rather than on continuation of a 
specific treatment. Thus, we classified patients who switched therapies as persistent if 
they continued on any antidepressant medication, not just the one initially prescribed. 
We also considered a patient with combination therapy a persistent user if the 
individual continued on one of any antidepressant medications without a significant 
gap. The fact that some other authors defined switching as discontinuation or excluded 
patients with combination therapy could explain the lower rate of discontinuation in 
our study. We believe that this is a strength of our study, as early discontinuation due 
to costs,[41] side effects,[15, 36] or low efficacy of treatments[42] may necessitate 
changes to other medications. Therefore, our study better reflects the realities of 
treatment over the initial 6-month period. 
 
Secondly, the introduction of Medicare Part D prescription drug plans may influence 
medication persistence. One of the most prevalent reasons that patients stopped taking 
their medications was the cost of the drugs[43] and inadequate insurance 
coverage.[44] Therefore, implementation of Medicare Part D could increase older 
Medicare beneficiaries’ ability to continue the medication therapy by relieving the 
burden of immediate medication costs.[45] We used the MCBS 2006-2008 data, and 
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our study sample of Medicare beneficiaries was eligible for the new coverage. As a 
result, we think that the new medication coverage may reduce cost-related non-
persistence and that the lower discontinuation rate in our study may be a reflection of 
positive effects of the new medication coverage policy among older adults. 
 
The 6-month rate of discontinuation of antidepressant treatments stratified by 
antidepressant class (SSRI/SNRI vs. TCA/Other) revealed that older beneficiaries 
taking SSRIs or SNRIs had a higher discontinuation rate than those using TCAs or 
other antidepressants. Clinical guidelines recommend SSRIs as an initial choice when 
patients require antidepressant treatments.[4] In other words, patients taking SSRIs are 
relatively healthier and less likely to have severe depression. By contrast, patients put 
on a TCA or a second generation antidepressant may have a higher chance of failure 
with SSRIs/SNRIs or may suffer from adverse events related to SSRIs/SNRIs. A study 
suggested that healthier patients were more likely to discontinue their medication 
therapy.[46] Similarly, SSRI/SNRI users are relatively healthier than TCA/Other 
antidepressant users, which may explain the higher rate of discontinuation in 
SSRI/SNRI users. 
 
According to the 2012 published HEDIS report, 66.3% of adults who were newly 
diagnosed with depression and treated with antidepressants in Medicare Health 
Maintenance Organizations (HMO) persisted with their medication therapy for at least 
12 weeks in 2011.[47] Similarly, 70.8% of persons enrolled in a Medicare Preferred 
Provider Organization (PPO) continued the treatment for at least 12 weeks. Regarding 
 33 
 
the national average of effective continuation phase treatment, 53.3% in Medicare 
HMO and 58.4% in Medicare PPO continuously used the antidepressants for at least 6 
months. While the HEDIS data provide important benchmarking information for our 
study, several key differences exist. Notably, our study included only older adults, 
while the HEDIS report is approaching whole Medicare beneficiaries, including aged 
and disabled individuals. Furthermore, the HEDIS measure is applicable to adults aged 
18 years or older who are diagnosed with a new episode of MDD and treated with 
antidepressants. Our study attempted to identify a new episode of antidepressant use 
among older adults diagnosed with depression during the study period; however, a 
new episode of antidepressant treatment was not necessarily a new diagnosis of 
depression or incident antidepressant utilization. Therefore, the rate of persistence in 
our study may be estimated higher than the national HEDIS average of persistence in 
Medicare beneficiaries.  
 
Discussion of Independent Predictors of Non-Persistence 
We found that older adults living in metropolitan areas were at significantly increased 
risk of antidepressant treatment discontinuation. Consistent with our finding, other 
studies have reported higher proportion of adherence/persistence among patients in 
rural areas compared to urban areas.[48, 49] A study by Ohl et al. suggested that HIV-
positive veterans living in rural areas were 24% more likely to be adherent to 
antiretroviral therapy compared to urban veterans (OR=1.24; 95% CI,1.1-1.6)[49] 
Another study conducted by Egede et al. also documented slightly higher adherence to 
diabetic medication therapy in rural patients than in urban patients.[48] Studies found 
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that people living in rural areas were older, more likely to be Non-Hispanic White, 
relatively lower levels of education, exhibited less use of substances, and were more 
likely to have a chronic medical condition.[49-51] In the published literature, older 
age and white race/ethnicity are consistently identified as predictors of better 
persistence in use of antidepressant medication.[6, 14, 18, 52, 53] Therefore, 
differences in demographic characteristics and comorbid conditions between rural 
residents and urban residents could explain the association between metropolitan areas 
and higher rates of medication discontinuation. 
 
Other studies, however, found no disparity in medication adherence between rural and 
urban residents[54, 55] or reported better adherence by urban patients compared to 
rural patients.[56] These studies showed that rural patients with a history of stroke 
were not significantly different in medication adherence compared to urban 
patients.[55] Similarly, adherence to cardiovascular medications was not significantly 
associated with a residence type,[54] with the exception of angiotensin-converting 
enzyme (ACE) inhibitors (for which rural people showed a higher discontinuation 
rate).[56] One explanation for a higher adherence in urban areas is that patients in 
metropolitan areas have more health care resources and better access to health care 
services,[57] and can therefore visit physicians or healthcare providers more often.[58] 
Urban patients can be diagnosed adequately and can manage their disease 
properly,[57] leading to a higher adherence to treatments. 
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The reasons for differences in treatment compliance between metropolitan and non-
metropolitan areas remain unclear. As patients with depression have shown different 
patterns of health service utilizations,[59] our finding on older adults with diagnosed 
depression may imply unique characteristics. Future research may be necessary to 
evaluate the reasons for a higher rate of antidepressant discontinuation among older 
adults living in metropolitan areas. 
 
Although our study focused on demographic and clinical characteristics to identify 
factors associated with medication persistence, it is important to note that there are 
many other factors affecting medication adherence beyond demographics and clinical 
characteristics, which may be difficult to measure using the claims data. For example, 
Bajcar’s conceptual model demonstrates patient’s perspective when taking 
medications.[60] According to Bajcar’s theory, patients’ need for medication 
information related to 4 concepts, including 1) making sense of medication taking, 2) 
medication-taking acts, 3) medication-taking self-assessment, and 4) context of 
medication taking. Further, Bajcar suggests that the decision to self-adjust medications 
or to not take the medication at all is related to patient’s significant information-
seeking activities. According to Bajcar, the decision to take (or not take) a medication 
is a cognitive process for individuals. Our study focused on non-cognitive factors and 
therefore was unable to quantify the effect of cognitive factors as suggested by 
Bajcar’s model. 
 
Limitations 
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This study has several limitations. First, the sample size is relatively small. The lack of 
significance of potential predictors of antidepressant discontinuation may be a result of 
small sample size. Secondly, this study may introduce misclassification bias by 
identifying patients diagnosed with depression using claims data; therefore, the 
prevalence of depression in Medicare beneficiaries may be underestimated in this 
study. Similarly, our study identified new episodes of antidepressant use among older 
adults diagnosed with depression during the study period. Since a new episode of 
antidepressant treatment is not necessarily indicative of newly diagnosed depression or 
incident use of antidepressants, our findings may apply to initiation and re-initiation of 
antidepressant therapy. 
 
Third, this study may introduce selection bias as participation in the MCBS is 
voluntary. Although the MCBS obtains high response rates across the four-year 
interviews (ranging from 82.6% at the first year of the interview to 67.3% at the fourth 
year),[61, 62] non-response may detract from the generalizability of our study’s 
findings. One study suggests that Medicare beneficiaries with older age or poor health 
condition were more likely to refuse participation in the MCBS survey or less likely to 
respond the survey.[62] Thus, the rate of non-persistence in our study might be 
underestimated. 
 
Fourth, we categorized patients with combination or switching therapy into either 
SSRI/SNRI or TCA/Other antidepressant subgroup based on the longest duration of 
therapy. This method of categorization may result in misclassification of subgroups if 
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patients took both classes of antidepressants for the similar/same duration of time. We 
observed 7 cases out of 18 combination therapy users and 1 case out of 7 switching 
therapy users that might influence estimates of discontinuation rate by the subgroups. 
Appendix B and C present persistence status and subgroup categorized among patients 
with combination therapy and switching therapy. 
 
Despite the noted limitations, our study has several strengths. First, the MCBS data is 
a nationally representative sample of Medicare beneficiaries, which allows our 
findings to be generalized to the entire population of older Medicare population. 
Second, following the implementation of Medicare Part D prescription drug plans in 
2006, self-reported medication event files were augmented with prescription related 
claims data. The potential recall bias might thus be minimized. 
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CONCLUSIONS 
Our study suggests that approximately 5% of older adults enrolled in Medicare 
programs are diagnosed with depression and half of these depressed older adults are 
treated with antidepressant medications. Nearly 1 in 5 of depressed older adults initiate 
antidepressant treatments following the diagnosis of depression, and those new users 
tend to persist in antidepressant therapy for at least 6 months. Older adults living in 
metropolitan areas are less likely to continue antidepressant use. 
 
Information obtained from this study can be used by both primary care physicians and 
policy administrators to improve care for older Medicare beneficiaries. Physicians and 
other healthcare providers can use the information obtained from this study to more 
fully evaluate the benefit-to-risk ratio of prescribing specific antidepressant 
medications to older adults they see. In addition, the descriptive information obtained 
in this study (e.g., treatment patterns, average length of treatment) provides points of 
discussion for physicians and others providing health care to older adults regarding 
barriers to persistence in use of antidepressant treatment and potential adverse event. 
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Table 1.1 Discontinuation rates of antidepressant medication treatments, overall and 
by antidepressant medication class 
Percentage  
of discontinuation rate  
Overall  
Antidepressant  
Medication Class 
Chi-sq 
(p-value) 
SSRI/SNRI TCA/Other 
Phase (N=99, %) (N=66, %) (N=33, %) 
Acute phase 
(84 days) 
13.1 13.6 12.1 0.83 
Continuation phase 
(180 days) 
30.3 34.9 21.2 0.16 
At 1 year 
(365 days) 
75.8 84.9 57.6 0.003
**
 
*
p<0.05, 
**
p<0.01, 
***
p<0.001 
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Table 1.2 Demographic characteristics of the study sample by persistent status 
Demographic Characteristics 
Overall  
(N=99) 
Persistence status 
p-value Nonpersistence 
within 6 month 
(N=30) 
Persistence 
within 6 month 
(N=69) 
Age (years)    
0.14 
65-74 43.4 43.3 43.5 
75-84 34.3 23.3 39.1 
85+ 22.2 33.3 17.4 
Gender (%)    
0.35 Male 26.3 20.0 29.0 
Female 73.7 80.0 71.0 
Race/ethnicity (%)    
0.45 
NHW 85.9 83.3 87.0 
Other 14.1 16.7 13.0 
NHB 8.1 6.7 8.7 
Hispanic 1.0 0.0 1.5 
Other 5.1 10.0 2.9 
US Region (%)    
0.57 
Northeast 17.2 13.3 18.8 
South 39.4 40.0 39.1 
Midwest 27.3 23.3 29.0 
West 16.2 23.3 13.0 
Residence type (%)    
0.10 Metropolitan area 57.6 70.0 52.2 
Non-metropolitan 42.4 30.0 47.8 
Marital status (%)    
0.18 
Married 33.3 23.3 37.7 
Widowed 52.5 66.7 46.4 
Divorced
1)
 14.1 10.0 15.9 
# of children living (%)    
0.21 
0 8.1 3.3 10.1 
1-2 29.3 40.0 24.6 
3+ 62.6 56.7 65.2 
Education (%)    
0.80 
No highschool diploma  51.5 46.7 53.6 
High school graduate 32.3 36.7 30.4 
≥ College degree 16.2 16.7 15.9 
Income (%)    
0.61 <$25,000 83.8 86.7 82.6 
≥ $25,000 16.2 13.3 17.4 
Abbreviation: NHW=non-Hispanic White; NHB=non-Hispanic Black 
1)
 Divorced includes Divorced/Separated/Never Married. 
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Table 1.3 Clinical characteristics of the eligible sample by persistent status 
Clinical Characteristics 
Overall 
(N=99) 
Persistence status 
p-value 
Nonpersistence 
within 6 month 
(N=30) 
Persistence 
within 6 month 
(N=69) 
Overall heath % % % 
0.19 Excellent/Good 43.4 53.3 39.1 
Fair/Poor 56.6 46.7 60.9 
Health compared to 1 yr ago     
0.96 
Better 11.1 10.0 11.6 
About the same 38.4 40.0 37.7 
Worse 50.5 50.0 50.7 
# Comorbidities     
Mean ± SD 4.9±3.1 4.4±3.1 5.1±3.0 0.75
1)
 
Median 4 4 4 - 
Hypertension (Yes, %) 83.8 80.0 85.5 0.49 
Diabetes Mellitus 32.3 23.3 36.2 0.21 
Dyslipidemia 61.6 56.7 63.8 0.50 
Cardiovascular disease 56.6 46.7 60.9 0.19 
Cerebrobascular disease 17.2 13.3 18.8 0.50 
COPD 39.4 33.3 42.0 0.42 
Cancer 10.1 3.3 13.0 0.14 
Arthritis 52.5 53.3 52.2 0.92 
Pain-related disease 73.7 73.3 73.9 0.95 
Other mental disorder 54.6 50.0 56.5 0.55 
Sleep disorder 17.2 16.7 17.4 0.93 
Alcohol/drug abuse 8.1 3.3 10.1 0.25 
Hypothyroidism 29.3 26.7 30.4 0.71 
Fluid/electrolyte disorders 48.5 56.7 44.9 0.28 
# Medication use     
Mean ± SD 5.3 ± 2.6 4.7 ± 2.4 5.6 ± 2.7 0.44
1)
 
Median 4.8 4.2 5.3 - 
SSRI  64.7 70.0 62.3 0.46 
SNRI 9.1 10.0 8.7 0.84 
TCA 8.1 6.7 8.7 0.73 
Other 18.2 13.3 20.3 0.41 
Antihypertensive medications 93.9 86.7 97.1 0.05 
Antidiabetic medications 21.2 13.3 24.6 0.21 
Cholesterol lowering meds 52.5 50.0 53.6 0.74 
Anticoagulants/warfarin 31.3 16.7 37.7 0.04 
PPI/H2RA 58.6 46.7 63.8 0.11 
NSAID 71.7 66.7 73.9 0.46 
Abbreviations: COPD=chronic obstructive pulmonary disease; NSAID=non-steroidal 
anti-inflammatory drugs 
1)
 t-test was performed. 
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Table 1.4 Independent predictors of non-persistence with antidepressant medication 
treatments 
Independent predictors 
Adjusted  
Odds Ratio 
95% Confidence 
Interval 
Age (years)   
65-74 (Reference) 1.0 NA 
75-84 0.4 0.1 - 1.3 
85+ 1.2 0.3 - 4.0 
Gender   
Male (Reference) 1.0 NA 
Female 2.1 0.7 - 6.9 
Race/ethnicity   
non-Hispanic White (Reference) 1.0 NA 
OTHER
1)
 0.8 0.2 - 3.1 
Residence type   
Non-metropolitan area (Reference) 1.0 NA 
Metropolitan area 3.5 1.2 – 10.2 
Clinical characteristics   
Fluid and electronic disorder (1=yes) 2.2 0.8 - 5.9 
Antihypertensive medications (1=yes) 0.2 0.04 - 1.6 
Warfarin (1=yes) 0.3 0.1 - 1.1 
Hosmer and Lemeshow Goodness-of-fit Test (P [χ2df=7 > 2.59]=0.92). 
Abbreviation: NA = not applicable 
1) 
OTHER includes non-Hispanic Black, Hispanic, and other race/ethnicity. 
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Figure 1.1 Overview of study design to identify older adults with depression and newly initiative antidepressant medication therapy 
 
 
 
 
Abbreviations: LBDT= look-back date, FUPDT=follow-up date 
Definition of Index date: the first date of diagnosis with depression 
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Figure 1.2 Summary of study inclusion and exclusion criteria applied for the 
identification of the final study population 
 
MCBS 2006-2008
(N=21,612)
MCBS 2006-2008
Beneficiary age ≥ 65 years
(N=17,799)
Age <65 years 
(N=3,813)
exclude
MCBS 2006-2008
1) Age ≥ 65 years
2) Community residents
(N=16,601)
exclude Facility stay 
(N=1,198)
MCBS 2006-2008
1) Age ≥ 65 years
2) Community residents
3) Diagnosis of depression
(N=739)
exclude No diagnosis code of 
depression at any time during 
the study period (N=15,862)
MCBS 2006-2008
1) Age ≥ 65 years
2) Community residents
3) Diagnosis of depression
4) New antidepressant users
5) ≥180 days follow-up
(N=99)
exclude
• No prescription records 
during the study period 
(N=367) and the follow-up 
period (N=21)
• Patients who used 
antidepressants in the 90 
days prior to the index date 
(N=230)
• Patients whose follow-up 
period was less than 180 
days from index date (N=86)
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Manuscript II. Use of Selective Serotonin Reuptake Inhibitors and the Risk of 
Upper Gastrointestinal Bleeding in Older Adults 
 
BACKGROUND 
Antidepressant medications are the third most frequently prescribed medicine in the 
US.[1] Approximately 11% of Americans over 12 years of age received antidepressant 
treatments, and 14.5% of older adults took antidepressant medications between 2005 
and 2008.[2] 
 
Due to a more favorable adverse event profile compared to other classes of 
antidepressants,[3, 4] selective serotonin reuptake inhibitors (SSRIs) have been widely 
used. In a large claims data analysis from 2002-2008 in the US, SSRIs were prescribed 
to 69.6% of new antidepressant users, followed by second generation antidepressants 
(mostly bupropion, 17.3%), and serotonin norepinephrine reuptake inhibitors (SNRIs, 
≈ 9.6%).[5] 
 
Association between SSRIs and Gastrointestinal Bleeding 
Recently, however, SSRIs have been the target of an important debate concerning 
safety, particularly in terms of an increased risk of gastrointestinal (GI) bleeding. In 
1999, de Abajo and colleagues conducted a population based case-control study using 
the United Kingdom general practice research database and reported a three-fold 
increased risk of upper GI bleeding among patients who taking SSRIs.[6] Since the 
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initial study, eight studies have found a positive association[7-14] and four have found 
a negative association.[15-18]  
 
Biological Plausibility of the Effect of SSRIs on GI Bleeding 
It has been postulated that SSRIs may impair platelet function during the thrombotic 
process.[19-21] Platelet aggregation is stimulated by the release of serotonin stored in 
platelets. As platelets themselves are not able to synthesize serotonin, they are 
dependent on the reuptake of serotonin from plasma. Therefore, serotonin reuptake 
inhibitors (e.g., SSRIs) may decrease the concentration of stored serotonin in platelets 
by blocking the reuptake of serotonin into platelets, resulting in impairment of platelet 
aggregation.[21]  
 
Another hypothesis posited that SSRIs directly increase acid secretion in the stomach 
[22] triggering ulcers and resulting in upper GI bleeding.[23] Animal testing further 
supports this hypothesis by confirming enhanced gastric acid secretion when low-dose 
aspirin was used concurrently with an SSRI.[24] As several observational studies 
found no significant associations between SSRI use and bleeding other than in the 
upper GI region (e.g., lower GI or intracranial hemorrhage),[25, 26] it has been 
suggested that the mechanism of GI bleeding may differ from the mechanism leading 
to other bleeding. This hypothesis may clarify why, in many observational studies, the 
bleeding risks of SSRIs were restricted to upper GI bleeding.  
 
Effect Modification by Concurrent Medications 
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While the association between SSRI use and GI bleeding is unclear, modified effects 
of SSRIs on upper GI bleeding with concomitant medication use have received 
considerable research attention. A meta-analysis pooling four observational studies 
found that the risk of upper GI bleeding increased 2.4 times with SSRI use; however, 
the risk increased 6.3 times with concomitant use of SSRIs and non-steroidal anti-
inflammatory drugs (NSAIDs).[27] Dall et al. tested the risk of upper GI bleeding 
when SSRIs were used with NSAIDs and/or low-dose aspirin. In this study, the odds 
ratio was 1.7 (95% Confidence Interval [CI], 1.0-2.8) for SSRIs associated with upper 
GI bleeding. The odds ratio increased to 8.0 (95% CI, 4.8-13.0) with use of both 
SSRIs and NSAIDs, and the risk was 28 times (95% CI, 7.6-103.0) higher in patients 
using SSRIs, NSAIDs, and aspirin together compared to patients using none of these 
medicines.[7] Furthermore, the increased risk of upper GI bleeding associated with 
SSRIs and/or NSAIDs was attenuated by using acid suppressing medication (OR=0.3; 
95% CI, 0.1-0.8).[9]  
 
Research in Older Adults 
National guidelines published by the American Psychiatric Association (APA) 
recommend review of concurrent medication use when patients suffer from GI 
bleeding after initiating SSRI therapy.[28] The possible link between SSRI use and GI 
bleeding or effect modification by concurrent medications may have substantial 
importance, especially in older adults who are already at higher risk of GI bleeding. 
As older adults generally have multiple comorbid conditions and take multiple 
medications, older adults are more likely to have additional risk factors for upper GI 
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bleeding, including higher use of NSAIDs, anticoagulants, and corticosteroids, and 
respiratory disease.[29-33] 
 
In this study, we examined the association between the use of SSRIs and the risks of 
upper GI bleeding in a community-dwelling population of older adults. We 
hypothesized that the use of SSRIs would increase the risk of upper GI bleeding in 
older adults and further, this risk would be modified by certain medications. 
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METHOD 
We performed a nested case-control study among older Medicare beneficiaries to 
quantify the effect of SSRI use on the increased risk of upper GI bleeding in older 
adults. 
 
Data Source 
We used the Medicare Current Beneficiary Survey (MCBS) Cost and Use files from 
2004 to 2008. The MCBS is a multipurpose survey of a nationally representative 
sample of aged and disabled individuals, which allows study results to be generalize to 
the whole population of Medicare beneficiaries in the US.[34] The MCBS survey 
questionnaire was originally designed by the Center for Medicare and Medicaid 
Services (CMS) to facilitate administration, monitoring, and assessment of the 
Medicare programs.[35]  
 
The MCBS has a unique feature, augmenting survey with Medicare Parts A, B and D. 
The MCBS Cost and Use files provide comprehensive information, including 
beneficiaries’ demographic and socioeconomic characteristics, health status and 
behaviors (e.g., smoking status, alcohol consumption), health insurance coverage, 
medical histories, prescription drugs, and dates of death. 
 
Cohort Identification 
We assembled a cohort of older adults over the age of 65 who were living in the 
community. We then restricted this cohort to include only beneficiaries whose claims 
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data was available from 2006 to 2008 and those with at least 1 year of continuous 
eligibility from the date of cohort entry. 
 
From this eligible population, we excluded community-dwelling older beneficiaries if 
they were diagnosed with certain diseases, including 1) Mallory-Weiss syndrome, 2) 
esophageal varices, 3) alcohol abuse, 4) liver cirrhosis, 5) cancer, 6) blood loss 
anemia, or 7) Helicobacter pylori infection. These conditions predispose patients to GI 
bleeding.[36, 37] We then followed eligible beneficiaries from the date of study entry 
until one of the following events: 1) diagnosed with upper GI bleeding; 2) death; or 3) 
end of the study period. The final sample size in the cohort was 13,240. Figure 2.1 
presents the conceptual design of this nested case-control study and Figure 2.2 
describes the inclusion and exclusion criteria of this study and the corresponding 
sample sizes.  
 
Case Identifications 
Within the larger cohort, we first identified all patients who had an episode of upper 
GI bleeding using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes using inpatient and outpatient medical 
claims. We then marked cases as those who were diagnosed with upper GI bleeding 
following 90 days after cohort entry. We set a 90-day window to ensure at least 90 
days to evaluate patient’s comorbid conditions and medication use before the events. 
We assigned an index date for each identified case based on the first observed date of 
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upper GI bleeding. During the follow-up period, we identified 152 cases of upper GI 
bleeding.   
 
The ICD-9-CM codes for upper GI bleeding that we utilized are presented in Table 
2.1. Based on the published literature, we comprehensively assessed ICD-9-CM codes 
for GI bleeding. While validity of the ICD-9-CM codes for upper GI bleeding/ 
hemorrhage varied across databases,[38-40] a study using databases from a large 
number of health plans in the US documented positive predictive values of 
approximately 60-65% for ICD-9-CM codes 531, 532, or 534, and less than 10% for 
ICD-9-CM codes 533 or 578.[38]  
 
Control Selection 
We used incidence density sampling to identify controls representative of the exposure 
distribution that gave rise to the case. We randomly selected controls from the large 
cohort of Medicare beneficiaries who had not been diagnosed with upper GI bleeding. 
Utilizing an incidence density sampling (also known as a risk-set sampling) method, 
we identified eligible controls by matching on age (+/- 5 years), sex, calendar year of 
cohort entry, and the Charlson comorbidity index scores (0, 1-2, ≥3).[41] We 
individually matched cases to controls using a 6:1 control-to-case ratio. While a 4:1 
control-to-case ratio is reported as the most efficient matching ratio,[42] a 6:1 
matching ratio as obtaining additional controls beyond 4 would not result in additional 
costs and could increase statistical power, particularly in large samples with high 
correlation between cases and matched controls or with low prevalence of exposure or, 
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alternatively, when assessing multiple potential exposures simultaneously.[35, 36] 
Controls were assigned an index date based on the date of their matched cases. The 
final sample eligible for study inclusion was 152 cases and 820 matched controls. 
 
Exposure Definition 
We looked back 90 days prior to the index date to identify patients with exposure to 
SSRIs. We used prescription drug event files linked to Medicare Part D claims data. 
Using the therapeutic class codes in prescription drug event files, we first identified 
the generic/brand names of possible antidepressants in subclass of ‘80’ 
(psychotherapeutic drugs) or ‘97’ (psychotherapeutic drugs). Next, we pulled the 
generic/brand names of antidepressants and then manually reviewed identified drugs 
to make sure all SSRIs were properly identified. The SSRIs that we identified included 
citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. 
 
Potential Confounders 
We assessed additional demographic and clinical characteristics that might influence 
the relationship between SSRIs and GI bleeding. Demographic characteristics 
included race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Other), 
US geographic region (Northeast, South, Midwest, West), residence type 
(metropolitan versus non-metropolitan area), marital status (married, widow, 
divorced/separated/never married), education (college degree or more, high school 
graduate, no high school diploma), and income (less than $25,000 vs. more than 
$25,000). We further identified self-reported overall health status (excellent/very 
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good/good versus fair/poor) and health status compared to one year ago (much 
better/somewhat better/about the same vs. somewhat worse/much worse) as potential 
confounders. 
 
Based on the published literature, we considered the following clinical conditions as 
potential risk factors for upper GI bleeding: a respiratory disease and psychiatric 
disorder;[33] a history of GI bleeding;[43] and concurrent medications, including 
NSAIDs,[29] anticoagulants (i.e., antiplatelet agents, low-dose aspirin, warfarin),[30, 
31] corticosteroids,[32] antihypertensive medications (i.e., angiotensin-converting 
enzyme inhibitors [ACEI], angiotensin-receptor blockers [ARB], calcium channel 
blockers [CCB], beta blockers, diuretics), cholesterol-lowering medications, 
antidiabetic medications, acid suppressing medications (i.e., proton pump inhibitor 
[PPI], histamine 2 receptor antagonist [H2RA]), anticonvulsants, and 
sedative/hypnotic medications.[44-46]  
 
We assessed the presence of the above risk factors within 90 days prior to the index 
date using inpatient/outpatient medical claims data and prescription drug files. We 
utilized the Elixhauser comorbidity index algorithm[41] to identify the comorbid 
conditions. We quantified patients who had diagnosis codes for upper GI bleeding in 
the first 90 days of cohort entry to control for a history of GI bleeding. The 
confounding medications were identified using the same approach used to identify 
SSRIs from prescription drug event files. We further identified use of antidepressants 
other than SSRIs as a potential confounder. 
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Evaluation of Effect Measure Modification by NSAID use 
We tested whether NSAID use is effect modifier in the association between SSRI use 
and upper GI bleeding. We classified medication exposure as four exclusive groups, 
including 1) SSRI user; 2) NSAID user; 3) Both SSRI and NSAID user; and 4) non-
user. We then estimated crude odds ratio and adjusted odds ratio for each exposure 
group compared to patients who did not use any of these two medications. 
 
Sample Size Estimation 
We performed sample size calculations to evaluate EMM of the association between 
SSRI and upper GI bleeding from NSAID use. In our sample size calculations, we 
held the two-tailed test at alpha level of 0.05 and the beta level at 0.20 (i.e. Power of 
80%) and used 6:1 ratio of the control group to the case group. We further needed 
proportion of SSRI and/or NSAID use in the control group as well as expected odds 
ratio due to exposure of SSRI and/or NSAID. We found these estimates based on a 
meta-analysis by Loke et al.[27] According to the meta-analysis, proportion of both 
SSRI and NSAID use in the control group would be 0.4% and expected odds ratio due 
to exposure of both medications would be 6.33 (95% CI, 3.40-11.82). Based on these 
assumptions, we estimated a sample size of 148 individuals for cases and 888 for 
controls. 
 
Descriptive Analyses and Conditional Logistic Regression Models 
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We first conducted bivariate analyses to summarize differences in baseline 
characteristics between cases and matched controls. As the controls were matched 
with the cases, we performed univariate conditional logistic regression for categorical 
variables and paired t-tests for continuous variables to confirm statistical significance. 
 
We then developed a conditional logistic regression model to estimate the effect of 
SSRI use on the risk of upper GI bleeding. We employed a conditional logistic 
regression model because of the matched design in selecting cases and controls.[47] 
Our dependent variable was an episode of upper GI bleeding (coded as 1=diagnosed 
with upper GI bleeding [case], 0=no evidence of GI bleeding [control]). The 
independent variable was use of SSRIs (coded as 1=SSRI users vs. 0=non-users within 
90 days prior to the index date).  
 
Based on the descriptive statistics obtained from bivariate analyses, we considered 
variables that had 5% or more difference in proportion between the cases and controls 
as potential confounders. Next, we manually added these variables sequentially into 
the model with assessment of the β-coefficient of the risk estimates of SSRIs. Any 
factors that changed the estimated β-coefficient by at least 10% were considered 
confounding and retained in the model. We also retained a basic demographic 
characteristic (i.e., race/ethnicity) in the model because of its clinical and social 
importance. After a final model resulted, we checked for multicollinearity by assessing 
variance inflation factor (VIF) values. We considered VIF values greater than 8 as 
indicative of potential correlations between independent variables.[48] 
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We estimated crude (unadjusted) and multivariable (adjusted) odds ratios and 
corresponding 95% confidence intervals. Adjusted odds ratios were estimated by 
simultaneously adjusting for potentially confounding covariates. As we utilized 
incidence density sampling to select controls, the odds ratio from our conditional 
logistic regression model approximates the incidence rate ratio.[49] 
 
All statistical tests were conducted with a two-tailed alpha of 0.05. All statistical 
analyses were performed using SAS software (SAS Institute Inc., Cary, NC, version 
9.3). 
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RESULTS 
We identified 152 cases and randomly selected 820 matched controls from the MCBS 
data from 2006 through 2008. As presented in Table 2.2, the cases and matched 
controls were comparable in matching factors, including age, gender, the year of 
cohort entry, and Charlson comorbidity index scores. The mean age of the cases was 
80.3 years old (± 7.8 years) compared to 79.7 years (± 7.3 years) in the controls. 
Approximately 40% of the cases were male and 60% of them were female. The 
selected controls had the same gender proportion as the cases. Most identified cases 
were eligible for the MCBS sample from 2006 (≈ 90%) and controls had the same year 
of cohort entry as the cases. Approximately 50% of the cases and controls have 
Charlson comorbidity index scores of 1 or 2. 
 
Table 2.3 presents demographic characteristics stratified by case and control status. 
Overall, the selected controls showed demographic characteristics similar to those of 
the cases. Most parents were non-Hispanic White (89.5% for cases versus 86.3% for 
controls), living in metropolitan areas (67.1% of cases vs. 70.2% of controls), and 
reported at least good health (60.5% in cases vs. 68.9% in controls). In addition, their 
income level was low (those whose income was less than $25,000 was 63.8% in cases 
and 57.6% in control). Cases were more likely to be widowed than controls (54.0% for 
cases vs. 43.1% for controls). 
 
In Table 2.4, we present clinical characteristics of cases and controls. Although we 
matched on an overall marker of comorbidity, the prevalence of chronic diseases was 
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higher in the cases than in the controls. The cases were more likely than the controls to 
have hypertension (52.6% of the cases compared to 17.7% of controls), cardiovascular 
diseases (42% in the cases versus 14.3% in the controls), dyslipidemia (31.6% in the 
cases vs. 10.1% in the controls), diabetes mellitus (21.1% vs. 10.7%), and chronic 
obstructive pulmonary disease (COPD, 15.8% vs. 7.0%). Similarly, pain-related 
disorders occurred more frequently in the cases (32.9%) than in the controls (11.6%). 
Fatigue was also more prevalent in the cases (15.1%) than in the controls (3.3%). 
 
The prevalence of concurrent medication use in the cases and controls within 90 days 
prior to the index date is presented in Table 2.5. The cases showed a higher prevalence 
of use of NSAIDs (20.4% for cases versus 12.4% for controls), anticoagulant agents 
(15.8% vs. 10.6%), and acid-suppressing medications (18.4% vs. 12.9%). In addition, 
the cases were more likely to use ACE inhibitors (21.1%) and diuretics (26.3%) 
compared to the controls (15.0%, 19.6%, respectively). There was no significant 
difference in the use of antidiabetics or cholesterol-lowering medications between the 
cases and controls. 
 
The results of the conditional logistic regression model designed to determine the risk 
of upper GI bleeding associated with SSRI use are presented in Table 2.6. Before 
adjusting for potential confounders, patients exposed to SSRIs were approximately 
30% more likely to be diagnosed with upper GI bleeding, although this association 
was not statistically significant (Odds Ratio [OR]=1.3; 95% Confidence Interval [CI] 
0.7-2.5). When controlling for race/ethnicity, certain medications (i.e., anticoagulants, 
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NSAIDs, systematic corticosteroids, acid suppressing medication, ACE inhibitors) and 
certain comorbid conditions (i.e., hypertension, cardiovascular diseases, dyslipidemia, 
COPD, fatigue, fluid/electrolyte disorder), the association became negative, although 
it was still not statistically significant (Adjusted OR [AOR]=0.7; 95% CI, 0.3-1.7). 
 
Table 2.7 presents the modified effects of SSRIs on upper GI bleeding by NSAIDs. 
Compared to patients who were exposed neither SSRIs and NSAIDs, patients who 
took SSRIs had almost same odds of developing upper GI bleeding as non-users, 
while patients who used NSAIDs were at 70% increased risk of upper GI bleeding 
relative to non-users (OR=1.7; 95% CI, 1.1-2.8). Older adults who took both SSRIs 
and NSAIDs were 2.9 times more likely to have upper GI bleeding than non-users 
(OR=2.9; 95% CI, 1.0-8.1); however, after we controlled for potentially confounding 
factors, the associations were no longer statistically significant. 
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DISCUSSION 
We tested the hypothesis that SSRI use was associated with an increased risk of upper 
GI bleeding among older adults. Our findings did not confirm the association. Further, 
after adjusting for confounding factors, we did not find a significant association that 
concurrent medications (i.e., NSAID) increased the risk of upper GI bleeding 
associated with SSRI use. 
 
While the results surrounding the link between SSRI use and upper GI bleeding are 
conflicting, our study supports the finding of no significant association.[15-17] A 
prescription event monitoring cohort study performed by Dunn et al. in England did 
not support a significant association between SSRI use and GI bleeding (RR=1.2; 95% 
CI, 0.9-1.7).[15] In addition, a multicenter case-control study using American medical 
records did not find that SSRI users were more likely to be hospitalized with upper GI 
bleeding (OR=1.3; 95% CI, 0.8-1.9).[17] Another population-based multicenter case-
control study failed to find any association between admission to a hospital for upper 
GI bleeding and highly selective SSRI use (OR=1.24; 95% CI, 0.88-1.76).[16] 
 
Several observational studies, however, identified a positive association between SSRI 
use and upper GI bleeding.[8, 9, 12] Dalton et al. found that SSRIs yields a 3.6 times 
increased risk of GI bleeding in a population in Denmark (RR=3.6; 95% CI, 2.7-
4.7).[8] Similarly, Vertel et al. reported that SSRI users in the Netherlands were 40% 
more likely to be hospitalized due to GI bleeding (OR=1.4; 95% CI, 1.2-1.6).[12] A 
Canadian study also duplicated this positive association (OR=1.4; 95% CI, 1.1-1.9)[9]  
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One of the possible reasons why our study did not find an association while others did 
is potential residual confounding. A recent study demonstrated that the number of 
comorbidities (excluding GI related disorders) was a significant predictor of upper GI 
bleeding.[37] It found an approximately 40% increased risk of GI bleeding over 
patients with a single comorbidity, as identified by the Charlson comorbidity 
algorithm (OR=1.4; 95% CI, 1.3-1.5). This association became stronger if patients had 
comorbidity index scores greater than or equal to 2 (OR=2.3; 95% CI, 2.1-2.4).  
 
In our study, we matched cases and controls on overall Charlson comorbidity index 
scores. As we minimized potential confounding by indication, our estimates might 
more accurately control for confounding related to comorbidity compared to other 
studies. In the published literature suggesting an increased risk of upper GI bleeding 
associated with SSRI, the risk estimates varied depending on how well the study could 
control for potential confounders (especially comorbid conditions). A cohort study 
using prescription and hospital discharge records found a 3.6 times increased risk of 
upper GI bleeding associated with SSRIs, adjusted for age, gender, and calendar 
year.[8] A population-based case-control study adjusted for age, gender, year, 
smoking status and use of anticoagulant and steroids found a 3-fold increased risk of 
upper GI bleeding in patients using SSRIs.[6] Another cohort study adjusted for 
comprehensive risk factors (i.e., age; gender; year; diabetes; history of GI bleeding; 
use of NSAIDs, aspirin, corticosteroids, anticoagulants, and acid-suppressing 
medications) suggested a hazard ratio of 1.1 for upper GI bleeding associated with 
 68 
 
serotonin reuptake inhibitors. In studies controlling for more comorbid conditions, 
estimates of the association between SSRIs and upper GI bleeding were closer to 1. 
Therefore, the established association between SSRI use and GI bleeding may be 
overestimated when potential confounders are not adequately controlled for.  
 
A study by van Walraven et al. examined this association in older adults in 
Canada.[11] They observed an approximately 10% increased risk of upper GI bleeding 
with a 1 unit increase in affinity for serotonin transporters. Although their study 
population was also older adults, direct comparison of the findings may be 
problematic because of some notable differences between the two studies. First, they 
classified antidepressant medications based on the level of affinity for the serotonin 
transporters and defined exposure as low, intermediate, and high based on serotonin 
reuptake inhibition. Thus, SSRIs were categorized into different groups if a degree of 
affinity was different. We used any SSRI exposure versus no exposure in the previous 
90 days, ignoring receptor affinity. Furthermore, their risk ratio was estimated 
compared to low-affinity medication users; however, we restricted exposure group to 
SSRI users and estimated the risk ratio compared to non-users. Second, they identified 
cases by hospitalization for acute upper GI bleeding, while we identified as cases all 
patients who had the diagnosis code for upper GI bleeding. When cases were defined 
by admission to a hospital for GI bleeding, it may be possible to miss patients who 
have less severe GI bleeding. 
 
Our study examined whether NSAID use modified the effect of SSRIs on upper GI 
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bleeding. Due to the small sample size, we could not obtain significant estimates. 
However, available evidence suggested that the concurrent medications that were 
additional risk factors for upper GI bleeding amplified the association between SSRI 
use and upper GI bleeding.[7, 9, 27, 50]  
 
Limitations 
We believe that our study can provide additional information about the association 
between SSRI use and upper GI bleeding, especially among older adults who are at 
higher risk. However, our study has several potential limitations. First, although we 
controlled for important confounders, we did not control for such factors (e.g., 
smoking). Second, misclassification bias may be introduced by using administrative 
claims data. We identified cases of upper GI bleeding using the ICD-9-CM diagnosis 
code. We may thus have missed patients who had GI bleeding if there was no 
diagnosis code for the bleeding. Therefore, the risk may be underestimated. Third, the 
study sample size was small, including 152 cases and 820 matched controls. Although 
the direction of the association was less influenced by a small sample size, the 
estimates may be less accurate in terms of lack of significance). 
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CONCLUSIONS 
In our study, we did not find an increased risk of upper GI bleeding associated with 
SSRI use in older adults. Further, after adjusting for confounding factors, we found 
that the effect of SSRIs on upper GI bleeding modified by NSAIDs was not 
significant. While the results of our study do not confirm other studies that reported an 
increased risk of upper GI bleeding resulting from NSAID use, our results highlight 
the importance of physicians weighing the risk to benefits when prescribing NSAIDs 
and SSRI’s simultaneously for older adults. As this study does not provide conclusive 
data to guide clinicians, clinicians must weigh the potential risks, including upper GI 
bleeding, when prescribing these medications. Patient counseling is an important 
component of risk management strategies when prescribing medications. Pending 
more definitive information on the risk of upper GI bleeding from SSRIs and 
NSAIDS, patients should be cautioned about this possible adverse event. 
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Table 2.1 ICD-9-CM codes for upper GI bleeding identification [38-40] 
Upper Gastrointestinal Bleeding ICD-9-CM code 
Gastrointestinal hemorrhage  
Gastrointestinal hemorrhage 578.0, 578.1, 578.9 
Upper gastrointestinal hemorrhage  
Bleeding gastric ulcer 531.0, 531.2, 531.4, 531.6 
Bleeding duodenal ulcer 
532.0, 532.2, 532.4, 532.5, 
532.6, 532.9 
Bleeding peptic ulcer 533.0, 533.2, 533.4, 533.6 
Bleeding gastrojejunal ulcer 534.0, 534.2, 534.4, 534.6 
Gastritis or duodenitis with hemorrhage 
535.01, 535.11, 535.41, 
535.51, 525.61 
Angiodysplasia or dieulafoy lesion of the 
stomach and duodenum with hemorrhage 
537.83, 537.84 
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Table 2.2 Confirmation of on matching factors between cases and controls 
Matching factors 
Case Control 
(N=152) (N=820) 
Age (years)   
Mean ± SD 80.3 ±7.8 79.7 ± 7.3 
Median 81 80 
Range 66-100 65-100 
Gender, N (%)   
Male 60 (39.5) 330 (40.2) 
Female 92 (60.5) 490 (59.8) 
Calendar year of cohort entry, N (%)   
2006 137 (90.1) 736 (89.8) 
2007 15 (9.9) 84 (10.2) 
Charlson comorbidity score, N (%)   
0 51 (33.6) 292 (35.6) 
1-2 77 (50.7) 405 (49.4) 
≥3 24 (15.8) 123 (15.0) 
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Table 2.3 Prevalence of baseline demographic characteristics between cases and 
controls 
Characteristic 
Cases 
(N=152) 
Control 
(N=820) 
Crude 
Odds Ratio 
95% CI 
Race/ethnicity % %   
non-Hispanic White  89.5 86.3 1.0 NA 
non-Hispanic Black  5.3 8.1 0.6 0.3 - 1.3 
Hispanic 2.0 2.7 0.7 0.2 - 2.4 
Other 3.3 2.9 1.1 0.4 - 2.9 
Geographic region     
Northeast 13.8 19.6 1.0 NA 
South 39.5 37.7 1.5 0.9 - 2.5 
Midwest 29.0 24.0 1.7 1.0 - 2.9 
West 17.1 17.6 1.4 0.7 - 2.6 
Unknown 0.7 1.1 0.9 0.1 - 7.4 
Residence type     
Metropolitan area 67.1 70.2 1.0 NA 
Non-metropolitan area 32.9 29.8 1.1 0.7 - 1.7 
Marital status     
Married 34.9 47.6 1.0 NA 
Widowed 54.0 43.1 2.0 1.3 - 3.2 
Divorced/Separated/Other 11.2 9.4 1.7 0.9 - 3.1 
Education      
No high school diploma 39.5 33.9 1.0 NA 
High school graduate 32.2 28.3 1.0 0.6 - 1.5 
College degree or more 27.6 37.0 0.7 0.4 - 1.0 
Unknown 0.7 0.9 0.7 0.1 - 5.8 
Income     
≥ $25,000 63.8 57.6 1.0 NA 
< $25,000 36.2 42.4 1.3 0.9 - 1.9 
Overall health status     
Excellent/Very good/Good 60.5 68.9 1.0 NA 
Fair/Poor 38.2 30.6 1.4 1.0 - 2.0 
Unknown 1.3 0.5 3.3 0.5 - 20.3 
General health compare to 1 year     
Much better/better/same  63.2 67.8 1.0 NA 
Much worse/Worse 36.2 32.0 1.2 0.8 - 1.7 
Unknown 0.7 0.2 2.4 0.2 - 27.6 
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Table 2.4 Baseline clinical characteristics between cases and controls 
Clinical Characteristic (%) 
Cases 
(N=152) 
Control 
(N=820) 
Crude Odds 
Ratio 
95% CI 
Cardiovascular disease 42.1 14.3 5.8 3.7-9.0 
Congestive heart failure 19.1 6.3 4.3 2.4-7.6 
Cardiac arrhythmia 24.3 8.7 3.7 2.3-6.0 
Valvular Disease 7.9 2.9 2.9 1.4-6.1 
Peripheral vascular disease 9.9 3.1 3.7 1.9-7.4 
Cerebrovascular disease 9.2 2.0 6.0 2.6-13.7 
Hypertension (Uncomplicated) 52.6 17.7 5.5 3.7-8.2 
Diabetes Mellitus (Uncomplicated) 21.1 10.7 2.3 1.4-3.6 
Dyslipidemia 31.6 10.1 4.4 2.9-6.8 
COPD 15.8 7.0 2.7 1.6-4.6 
Hypothyroidism 11.8 4.4 2.9 1.6-5.4 
Renal failure 11.8 4.6 2.8 1.5-5.2 
Major depression 5.9 1.0 6.0 2.3-15.6 
Fatigue 15.1 3.3 5.6 3.1-10.2 
Pain 32.9 11.6 3.7 2.5-5.7 
Rheumatoid arthritis/Osteoporosis 13.2 4.0 3.6 2.0-6.6 
Fluid/Electrolyte disorder 20.4 4.4 5.5 3.2-9.5 
Coagulopathy 4.6 1.0 5.0 1.7-14.4 
History of GI bleeding 0.7 0.2 2.8 0.3-31.2 
Abbreviation: COPD=chronic obstructive pulmonary disease. 
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Table 2.5 Concurrent medication use between cases and controls 
Concurrent Medication Use (%) 
Cases 
(N=152) 
Control 
(N=820) 
Crude 
Odds Ratio 
95% CI 
Other antidepressant medications
1)
 7.2 3.1 2.5 1.2-5.2 
NSAIDs 20.4 12.4 1.9 1.2-2.9 
Anticoagulants 15.8 10.6 1.6 0.9-2.6 
Corticosteroids 7.2 6.5 1.2 0.6-2.4 
Acid suppressing medication 18.4 12.9 1.5 1.0-2.5 
Hypertension agents 45.4 38.1 1.4 1.0-2.0 
ACEI 21.1 15.0 1.5 1.0-2.4 
ARB 10.5 8.3 1.3 0.7-2.3 
Calcium channel blocker 17.1 12.7 1.4 0.9-2.3 
Beta blockers 22.4 17.8 1.3 0.9-2.0 
Diuretics 26.3 19.6 1.4 1.0-2.2 
Diabetic medications 9.2 11.1 0.8 0.4-1.4 
Cholesterol-lowering medications 23.0 19.3 1.3 0.8-2.0 
Statins 18.4 18.2 1.0 0.7-1.6 
Antiparkinsonian agents 1.3 2.1 0.6 0.1-2.7 
Anticonvulsants 4.0 4.4 0.9 0.4-2.2 
Sedative hypnotics 5.9 2.2 3.1 1.3-7.3 
Abbreviation: NSAIDs=non-steroidal anti-inflammatory drugs; ACEI=angiotensin-
converting enzyme inhibitors; ARB=angiotensin-receptor antagonists 
1)
 Other antidepressant medication included serotonin norepinephrine reuptake 
inhibitor (SNRI), tricyclic agents, and other class of antidepressant (i.e. bupropion, 
mirtazapine, reboxetine, trazodone). 
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Table 2.6 Association between use of SSRI and upper GI bleeding 
 
Cases 
(N=152) 
% 
Control 
(N=820) 
% 
Crude Odds Ratio 
(95% CI) 
Adjusted Odds Ratio
1)
 
(95% CI) 
N (%) N (%) 
SSRI use 
12 
(7.9%) 
50 
(6.1%) 
1.3 
(0.7 – 2.5) 
0.7 
(0.3 – 1.7) 
1)
Adjusted odds ratio was found after controlling for race/ethnicity, use of NSAIDs, 
anticoagulant agents, oral corticosteroids, acid suppressing medications, other 
antidepressant medication; comorbid conditions including uncomplicated 
hypertension, cardiovascular disease, dyslipidemia, COPD, fluid/electrolyte disorder, 
and fatigue. 
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Table 2.7 Evaluation of the interaction between SSRI and NSAID use on Risk of 
upper GI bleeding compared with non use of NSAIDs and SSRIs 
Category 
Cases 
(N=152) 
Control 
(N=820) Crude Odds Ratio 
(95% CI) 
Adjusted Odds Ratio
1)
 
(95% CI) 
N (%) N (%) 
Non-users 
115 
(75.6%) 
681 
(83.1%) 
1.0 (reference) 1.0 (reference) 
SSRI only 
6 
(4.0%) 
37 
(4.5%) 
1.0 
(0.4-2.4) 
0.5 
(0.2-1.6) 
NSAID 
only 
25 
(16.4%) 
89 
(10.8%) 
1.7  
(1.1-2.8) 
1.5 
(0.8-2.8) 
Both 
6 
(4.0%) 
13 
(1.6%) 
2.9 
(1.0-8.1) 
1.8 
(0.5-6.7) 
1)
Adjusted odds ratio was found after controlling for race/ethnicity, anticoagulant 
agents, oral corticosteroids, acid suppressing medications, other antidepressant 
medication; comorbid conditions including uncomplicated hypertension, 
cardiovascular disease, dyslipidemia, COPD, fluid/electrolyte disorder, and fatigue. 
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Figure 2.1 Conceptual study design: a nested case-control study to evaluate the effect of SSRIs on rate of upper GI bleeding 
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Figure 2.2 Sample selection inclusion and exclusion criteria 
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Manuscript III. A Systematic Literature Review: Effect Measure Modification 
and Sample Size Considerations in Observational Studies 
 
BACKGROUND 
Effect Measure Modification (EMM) is a phenomenon in which an association 
between an exposure and outcome varies by a third factor.[1] When EMM occurs, 
estimates of the association differ at different levels of the effect modifier, therefore 
the overall estimate of the association may be misleading.[2, 3] Unlike confounding in 
observational studies, EMM should be described and reported separately.[2, 3] 
Therefore, evaluating and characterizing EMM may be crucial when examining a 
potential association in data analysis. 
 
Common statistical methods to identify EMM include stratification and regression 
analysis.[4] Stratification is the assembly of subgroups by strata of the potential effect 
modifier followed by the evaluation of stratum-specific associations of exposure with 
the outcome of interest if heterogeneity is present.[2] Another method to test EMM is 
by testing the interaction terms in a regression model (e.g., effect modifier x 
independent variable [exposure of interest]). 
 
An important consideration for formal evaluation of EMM is to have adequate 
statistical power to quantify the association across categories or levels of the effect 
modifying factor. A stratified analysis dividing the sample into subgroups generally 
requires a large sample size. Smith and Day suggested that an at least four times larger 
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sample size was required to evaluate EMM compared with the sample size required to 
assess a main association under optimal conditions (e.g., 50% of the study population 
classified as an exposure and 50% being exposed to the potential effect modifier).[5] 
If the prevalence of the exposure or effect modifier is lower or higher than 50%, then 
the sample size to detect EMM is typically larger.[5]  
 
When seeking to evaluate EMM, researchers should conduct an analysis and report the 
sample size considerations related to the EMM in the medical literature.  
However, how the sample size considerations are determined in a study is less well 
understood, especially in research related to EMM utilizing large sets of 
administrative data.  
 
In this study, we performed a systematic literature review of published articles 
reporting EMM and characterized sample size considerations related to EMM reported 
in these studies. We hypothesized that few published pharmacoepidemiologic studies 
formally assessing EMM would utilize and present formal sample size calculations in 
the published manuscript. 
 
 87 
 
METHODS 
We performed a systematic literature review. To identify recently published articles of 
interest, we searched the PubMed electronic database from January 1, 2008 to June 30, 
2013. As the focus of this manuscript is the incorporation and presentation of sample 
size calculations or estimates related to effect measure modification in 
pharmacoepidemiological studies, we searched using the following terms: effect 
measure modification; effect modification; statistical interaction; biological 
interaction; epidemiology; epidemiological study; observational study; case-control; 
cohort study; cross-sectional; and medication. We further limited the search to English 
language articles and human subject studies.  
 
We first used a computerized literature search to identify relevant articles by reading 
the titles and abstracts. Articles identified as potentially relevant through this 
preliminary search were retrieved and reviewed systematically to eliminate articles 
whose study base did not include medication use or an observational study. We further 
excluded studies if the effect measure modification being evaluated in the study was 
not related to medication use (e.g. age, race/ethnicity, socioeconomic characteristics). 
From these articles, we identified new articles by reviewing the reference lists and 
retrieving the articles.  
 
After completion of the literature review, the literature was summarized by first 
describing the ways in which effect measure modification was used in the identified 
studies, including whether its assessment was a primary or secondary objective of the 
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study, and the major findings related to EMM. Second, we characterized the 
incorporation and presentation of sample size calculations in the identified studies. We 
developed a table that denotes whether sample size calculations related to EMM were 
performed and, if they were performed, what power resulted. For this study, analyses 
were largely descriptive and included frequencies to summarize the percentage of 
studies including specific sample size calculations. 
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RESULTS 
Using the provided search keywords, we initially found 685 publications. By 
reviewing the titles and abstracts of the potential literature, we selected 21 studies and 
eliminated 664 articles. The most frequent reasons for exclusion included the 
following: 1) the research topic was not related to EMM/association/statistical 
interactions (e.g., treatment effect, regimen/dose modification, prevalence of drug-
drug interaction; n=311); 2) the study design was not observational (e.g., an 
experimental design; n=148); and 3) the effect modifier was not related to medication 
use (e.g., age, race/ethnicity, certain disease/health condition, or genetic type; n=205). 
 
In Table 3.1, we present the characteristics of the included studies and state whether 
sample size considerations were presented in the study. In the included studies, the 
research questions were mostly related to risk assessments, varying from predictors of 
the increased risk of mortality associated with a psychotic disorder to associations 
between glycemia and lipid levels among patients with diabetes mellitus. The most 
popular effect modifier in the review was the use of cholesterol-lowering medications, 
including statins.  
 
While wide variation in methods to evaluate EMM existed, the two most common 
methods to evaluate the EMM were likelihood ratio testing after stratification or 2-
way interactions using the Wald test. The EMM was mostly tested as a secondary 
objective of the study (N=20), not as a primary objective (N=1). None of the studies in 
the review presented sample size considerations to detect the EMM; however, 3 
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publications mentioned the sample size considerations but did not present enough 
information to fully assess the required sample size to adequately assess EMM. 
 
A study performed by Dratva et al. provided the most detailed information regarding 
the sample size consideration among the reviewed literature.[6] They employed a 
prospective cohort study to examine the association between the menstruation cycle 
and bronchial hyper-reactivity. Using the population-based Swiss cohort study on air 
pollution and lung disease in adults (SAPALDIA II), they found 571 eligible 
individuals to examine the primary hypothesis (association between the menstruation 
cycle and bronchial hyper-reactivity). As a second step, they assessed the impact of 
oral contraceptive use on the hypothesized association. To achieve this objective, they 
enlarged the main study sample by including women currently using oral 
contraceptive, and found 130 more eligible women during this consideration. The 
authors preliminarily evaluated the EMM using interaction terms in the logistic 
regression model and then stratified the sample by oral contraceptive use status. They 
confirmed a significant interaction between the menstruation cycle and oral 
contraceptive use. When performing the stratified analyses, the authors observed 
insignificant effects of the menstruation cycle on the reduced risk of bronchial hyper-
reactivity modified by oral contraceptive use due to a lack of power.  
 
Mordukhovich et al. evaluated whether calcium channel blockers modified the effects 
of low-level environmental arsenic exposure on the prolonged QT interval as a 
secondary objective.[7] They initially utilized 2,280 individuals in their cohort. After 
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applying the inclusion and exclusion criteria, they found 226 eligible individuals to 
test the primary objective in a cross-sectional design. Using 2-way interaction terms in 
a regression model, they tested the interaction between arsenic exposure and calcium 
channel blocker use. However, they did not further report the results as the interaction 
was not significant. The authors also noted in the discussion that the effect 
modification by calcium channel blockers was not significant, potentially due to a 
small sample size. 
 
Henz et al. reviewed the comorbid conditions and concurrent medications to identify 
predictors affecting the serum potassium concentration in patients admitted to the 
hospital.[8] They employed a retrospective cross-sectional study and utilized 10,320 
patient records. As the primary finding, they reported that certain medications and 
comorbidities influenced the serum potassium concentrations. Using 2-way 
interactions in a regression model, they further found significant drug-drug 
interactions between angiotensin converting enzyme inhibitors and K-sparing diuretics 
and between beta blockers and non-steroidal anti-inflammatory drugs, which both 
affected the serum potassium concentration. However, they did not confirm the 
interaction between loop diuretics and angiotensin receptor blockers. With respect to 
the insignificant interactions, the authors suggested that the power might be limited 
even though the study sample size was relatively large. 
 
The other studies did not mention the sample size for assessing the EMM or 
interactions. Among these 18 studies, 10[9-18] confirmed significant 
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interactions/EMM, whereas 6[19-24] did not find significant interactions/EMM and 
2[25, 26] found statistical significance in one group (with significant estimates not 
presenting in all subgroups).   
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DISCUSSION 
We found that none of the studies performed sample size calculations specifically 
related to the EMM, although 14.3% of the identified studies mentioned sample size-
related issues in the study. Only one study described the process of expanding the 
sample size to achieve the study objectives related to EMM; two other studies 
mentioned a problematic small sample size to explain insignificant interactions in the 
study findings.  
 
One potential reason for the lack of sample size consideration in the reviewed articles 
would be the nature of an observational study. In contrast to clinical trials, which 
should be conducted as specified in the planned protocol, observational studies utilize 
data already collected or manipulate a closed cohort to examine associations. 
Therefore, the authors often described an eligible population for the study but did not 
provide a priori consideration of the minimum number of samples required to obtain 
accurate estimates of the association. Furthermore, based on our review, we found that 
most of the studies sought to assess the EMM as a secondary objective. Considering 
that published articles usually perform sample size calculations to test the main 
association,[27] expecting the presentation of additional sample size calculations for 
the secondary objective might be unreasonable. 
 
The substantial importance of adequate power in a study emphasizes the need to 
conduct sample size calculations in epidemiological studies (e.g., case-control studies 
and cohort studies).[27] A small sample size or more importantly, lack of statistical 
 94 
 
power may not change the direction of the association between the exposure and the 
outcome of interest.[3] However, the estimates of the association may lack precision 
as evidenced by wide confidence intervals.[3] Even in the case utilizing a large sample 
of administrative data, a large study population does not necessarily mean a higher 
prevalence of the exposure of interest or effect modifier. Therefore, considering the 
sample size for a specific study aim in the method sections can ensure the acquisition 
of accurate estimates with adequate power to detect the association.   
 
There are some suggestions to present observational studies in more informative ways. 
The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) proposed 21 check points that authors should address in reporting the 
results of an observational study.[28] In particular, the STROBE guidelines 
recommend that interaction/EMM analyses should be preferably presented as separate 
effects of the two exposures and as their joint effect using one reference category. By 
providing this sufficient information, readers can calculate the interactions/EMM on 
additive and multiplicative scales. Another study performed by Knol et al. further 
suggested a four-step presentation of the EMM or interactions in observational 
studies.[29] The crucial point that the study provided was reporting the estimates with 
a 95% confidence interval for each stratified cell. Again, the reason for presenting this 
information is to provide the full findings to the readers to increase the transparency of 
the study.  
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Our study adds one more point to improve the reporting of the EMM or interactions. 
Authors should provide consideration of the sample size calculation to evaluate the 
EMM/interactions in addition to describing the actual eligible sample size from the 
data. While EMM or interaction is widely assessed in epidemiological studies, 
ensuring adequate power for the research is a practical issue to obtain accurate 
estimates. While it is well known that sample size and power are important 
considerations for primary endpoints, other researchers suggest that similar 
considerations should be made when evaluating EMM.[4] Practically however, 
manuscript limitations may not provide adequate space to discuss all methodological 
considerations, including sample size related to EMM. With increased research on 
gene-gene interaction,[30] more studies will investigate and publish EMM. 
Presentation of sample size considerations is important to the reader, particularly when 
no association (or no effect measure modification) is reported. As evaluation of EMM 
is typically performed as secondary analyses, consensus on publication of sample size 
considerations in the pharmacoepidemiologic scientific community is warranted. By 
including the sample size considerations, the research can clearly demonstrate that the 
estimates are reliable and accurate and have adequate power. Therefore, the authors 
can perform better quality research, and the readers can easily analyze the results 
presented in the study.   
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CONCLUSIONS 
Our study evaluated the degree of reporting the sample size considerations related to 
EMM in the published medical literature. Studies examining the EMM largely failed 
to report sample size calculations to assess the associations of interest. This 
methodologically focused paper provided important insight for researchers on the 
correct (or incorrect) reporting of sample size related issues in the published medical 
literature by demonstrating what is currently being done and providing 
recommendations for future publications. 
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Tables 3.1 Characteristics and sample size considerations of the studies included 
Study 
No 
Author Research question EMM evaluated Method used 
Result 
(primary/ 
secondary) 
Sample size 
presented/ 
discussed 
1 
Aikens et al. 
(2009)[9] 
Glycemic control associated 
with depressive symptom 
severity 
Antidiabetic medication 
regimen (oral vs. insulin) 
2-way interaction Secondary No 
2 
Allen et al. 
(2009)[10] 
Arotic atherosclerosis 
associated with air pollution 
Statin use modified the 
effect of pollution on arotic 
calcification 
2-way interaction Secondary No 
3 
Almeida et al. 
(2012)[11] 
Total plasma homocysteine 
(tHcy) associated with 
depression 
Aspirin modifier on tHcy 2-way interaction Secondary No 
4 
Bruneau et al. 
(2012)[26] 
Hepatitis C virus (HCV) 
infection associated with 
prescription opioid injection 
Heroin use modified HCV 
infection rates. 
2 way interaction Secondary No 
5 
Chen et al. 
(2011)[12] 
Risks of cataracts associated 
with age 
Diabetic mellitus, folate 
level, antihypertensive 
medication use 
Stratified by risk factors 
of cataracts and 
evaluated EMM using 
likelihood ratio testing 
Secondary No 
6 
Dieset et al. 
(2012)[13] 
high sensitivity CRP 
(hsCRP) cytokine 
associated with CVD risk 
factors 
second generation 
antipsychotics modifies 
effects of CVD risk factors 
2-way interaction Secondary No 
7 
Dratva et al. 
(2010)[6] 
Bronchial hyperreactiveity 
associated with time of 
menstrual cycle 
Effect modifier of oral 
contraceptives 
Preliminarily evaluated 
EMM using likelihood 
ratio test; further 
assessed EMM stratified 
by oral contraceptive use 
status 
Secondary Yes 
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Tables 3.1 Characteristics and sample size considerations of the studies included (Continued) 
Study 
No 
Author Research question EMM evaluated Method used 
Result 
(primary/ 
secondary) 
Sample size 
presented/ 
discussed 
8 
Farzaneh-Far et 
al. (2009)[19] 
Inflammatory biomarkers 
associated with n-3 fatty 
acid levels 
Modified by Statin use 2-way interaction Secondary No 
9 
Hayashino et 
al. (2012)[20] 
Diabetes distress (measured 
by the PAID scale) 
associated with poor 
glycemic control 
Effects of the PAID scores 
modified by diabetic 
therapy (diet control vs. use 
of antidiabetic medications) 
on HbA1c level 
Evaluated interactions 
using likelihood ratio 
tests 
Secondary No 
10 
Henz et al. 
(2008)[8] 
Comorbidities and 
comedications predicting 
blood potassium 
concentration  
ACEI, cyclosporine, and 
loop/potassium-sparing 
diuretics modified the 
association between GFR 
and serum potassium level 
2-way interaction using 
the Wald test 
Secondary Yes 
11 
Hermann et al. 
(2009)[14] 
Risk of colorectal adenomas 
associated with lifestyle 
factors and obesity 
Folate intake modified the 
association between alcohol 
consumption and risk of 
adenoma 
2-way interaction using 
the Wald test 
Secondary No 
12 
Maahs et al. 
(2010)[15]  
Association between 
glycemia and lipid level in 
patients with type I diabetes 
mellitus 
Dyslipidaemia medication 
use 
Stratified by 
dyslipidaemia 
medication usage status; 
likelihood ratio testing 
Secondary No 
13 
Mordukhovich 
et al. (2009) [7] 
QT interval duration 
associated with 
environmental arsenic 
exposure 
Effect modification by use 
of calcium channel 
blockers; or antioxidant 
intake 
2-way interaction Secondary Yes 
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Tables 3.1 Characteristics and sample size considerations of the studies included (Continued) 
Study 
No 
Author Research question EMM evaluated Method used 
Result 
(primary/ 
secondary) 
Sample size 
presented/ 
discussed 
14 
Moyers et at. 
(2010)[21] 
Exercise parameters (i.e., 
heart rate recovery, exercise 
capacity and time) 
associated with serum n-3 
fatty acid levels 
Modified association by 
statin or beta blocker use  
2-way interaction Secondary No 
15 
Neuhouser et 
al. (2010)[16] 
Sex hormone concentrations 
associated with dietary fat 
intake in postmenopausal 
breast cancer survivors 
Tamoxifen modifier; effect 
modification between 
tamoxifen use and fat intake 
2-way interaction Secondary No 
16 
Rajanna et al. 
(2012)[17] 
HbA1c level associated with 
Fasting morning glucose 
Cholesterol controlling 
medication (i.e. statins, 
niacin, and fibrates) 
modifiers 
2-way interaction Primary No 
17 
Ross et al. 
(2011)[18] 
Weight change associated 
with Insomnia 
Sleep medications modified 
the association 
2-way interaction Secondary No 
18 
Samadder et al. 
(2011)[22] 
Colorectal cancer associated 
with inflammatory bowel 
disease 
Modification of risk by 
statin and NSAID use 
Stratified by medication 
use; evaluating EMM 
using likelihood ratio 
testing 
Secondary No 
19 
Shadman et al. 
(2009)[23] 
Risk of colorectal cancer 
associated with 
NSAIDs/statins use 
Effects of NSAIDs use on 
colorectal cancer  modified 
by statin use  
2-way interaction Secondary No 
20 
Suvisaari et al. 
(2013)[25] 
Predictors of mortality in 
patients with psychotic 
disorder 
Antipsychotic medication 
use modified the link 
between primary psychotic 
disorder and mortality 
Stratification; evaluation 
using likelihood ratio 
testing 
Secondary No 
  
 
1
0
3
 
Tables 3.1 Characteristics and sample size considerations of the studies included (Continued) 
Study 
No 
Author Research question EMM evaluated Method used 
Result 
(primary/ 
secondary) 
Sample size 
presented/ 
discussed 
21 
Wu et al. 
(2010)[24] 
All cause of mortality/CVD 
death associated with 
genetic variations in the 
RAS genes 
Effect of RAS-gene-
genotypes modified by use 
of ACE inhibitors 
2-way interaction Secondary No 
CVD=Cardiovascular disease; PAID= Problem Areas in Diabetes; RAS=Rrennin-angiotensin system; ACEI=Angiotensin converting enzyme 
inhibitor; NSAID = Non-steroidal anti-inflammatory drugs; GFR= Glomerular filtration rate 
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APPENDICES 
Appendix A. Prevalence of antidepressant medication use 
Category Antidepressants 
Antidepressant 
prescription records in 
MCBS 2006-2008 
755 prescription 
records (by the 99 
eligible sample) 
Eligible sample (N=99, 
multiple counted by 
using multiple meds)  
Eligible sample (N=99, 
single count, subgroup 
classified ) 
N % N % N % N % 
SSRIs 
Citalopram 4679 9.3 80 10.6 13 10.4 9 9.1 
Escitalopram 5658 11.3 172 22.8 26 20.8 23 23.2 
Fluoxetine 4077 8.1 36 4.8 6 4.8 5 5.1 
Paroxetine 4872 9.7 24 3.2 4 3.2 3 3.0 
Sertraline 6782 13.5 126 16.7 19 15.2 17 17.2 
SNRIs 
Desvenlafaxine 10 0.0 - - - - - - 
Duloxetine 2374 4.7 61 8.1 9 7.2 6 6.1 
Venlafaxine 3288 6.6 22 2.9 3 2.4 3 3.0 
TCA 
Amitriptyline 3458 6.9 30 4.0 7 5.6 5 5.1 
Amoxapine 1 0.0 - - - - - - 
Clomipramine 142 0.3 - - - - - - 
Desipramine 76 0.2 - - - - - - 
Doxepine 733 1.5 - - - - - - 
Imipramine 387 0.8 - - - - - - 
Maprotiline 10 0.0 - - - - - - 
Nortriptyline 681 1.4 14 1.9 3 2.4 2 2.0 
Protriptyline 13 0.0 - - - - - - 
MAOIs Phenelzine 89 0.2 - - - - - - 
Other 
Bupropion 2539 5.1 45 6.0 8 6.4 5 5.1 
Mirtazapine 3692 7.4 70 9.3 14 11.2 13 13.1 
Trazodone 4673 9.3 75 9.9 13 10.4 8 8.1 
Nefazodone 65 0.1 - - - - - - 
Total 50122 100.0 755 100.0 125 100.0 99 100.0 
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Appendix B. Persistence status and classified subgroup in patients with combination therapy 
No 
Duration of Therapy 
Persistence 
Status 
Subgroup 
Category 
Comments 
(medications in combination) SSRI SNRI TCA Other 
Therapy 
Days 
Combo1 355 . . 244 355 persist SSRI Escitalopram/Trazodone 
Combo2 323 . . 136 323 persist Other Sertraline/Trazodone 
Combo3 5 . . 7 7 non-persist Other
*
 Sertraline /Trazodone 
Combo4 365 . . 365 365 persist SSRI
*
 Sertraline /Bupropion 
Combo5 . 30 . 365 365 persist Other Duloxetine/Mirtazapine 
Combo6 335 . . 365 365 persist Other
*
 Fluoxetine /Trazodone/Bupropion 
Combo7 177 191 365 . 365 persist Other
*
 
Sertraline, Duloxetine 
/Amitriptyline 
Combo8 357 . . 365 365 persist Other
*
 Escitalopram/Trazodone 
Combo9 116 . . 117 117 non-persist Other
*
 Citalopram/Mirtazapine 
Combo10 . 265 67 133 265 persist SSRI 
Duloxetine/Amitriptyline, 
Bupropion 
Combo11 224 . 47 . 224 persist SSRI Escitalopram/Nortripyline 
Combo12 . 365 . 335 365 persist SSRI
*
 Duloxetine/Trazodone 
Combo13 60 . . 30 60 non-persist SSRI Paroxetine/Mirtazapine 
Combo14 108 . . 90 108 non-persist SSRI Citalopram/Trazodone 
Combo15 128 . . 2 128 non-persist SSRI Escitalopram/Trazodone 
Combo16 30 144 . 330 330 persist Other 
Escitalo,Citalopram, Duloxetine 
/Trazodone, Mirtazapine 
Combo17 231 . 323 241 323 persist Other 
Citalopram /Amitriptyline, 
Trazodone 
Combo18 300 . . 72 300 persist SSRI Fluoxetine/Trazodone, Bupropion 
* This categorization may result in misclassification of the subgroups. 
Subgroup category: SSRI=SSRI/SNRI; Other=TCA/Other antidepressant 
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Appendix C. Persistence status and classified subgroup in patients who switched medications 
No 
Duration of Therapy 
Persistence  
Status 
Subgroup 
Category 
Comments 
(Switching From-To) SSRI SNRI TCA Other 
Therapy 
Days 
Switching-1 211 . . . 211 persist SSRI SSRI - SSRI 
Switching-2 30 . . 23 53 non-persist SSRI Other - SSRI 
Switching-3 . . 30 30 60 non-persist Other TCA - Other 
Switching-4 252 . . 117 365 persist SSRI SSRI - Other 
Switching-5 43 96 . . 137 non-persist SSRI SNRI - SSRI 
Switching-6 30 . . 30 60 non-persist Other
*
 Other - SSRI 
Switching-7 270 . . . 270 persist SSRI SSRI - SSRI 
* This categorization may result in misclassification of the subgroups. 
Subgroup category: SSRI=SSRI/SNRI; Other=TCA/Other antidepressant 
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